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3 Summary 
3.1 Research question and Objectives 
Patient safety is a highly prioritized area within the provision of public and private health 
care services in both the European Union (EU) as a whole, member states, as well as in 
associated states. Risk governance giving preference to patient safety, includes regulation 
as an important management tool. Complementary and Alternative Medicine (CAM) is, in 
Europe, regulated either as conventional, complementary or alternative medicine, or not 
regulated at all. CAM regulation is, however, different in each of the 39 European 
countries included in the CAMbrella WP2 survey. Consequently an essential question is; 
What are the patient safety implications of the European disharmonious landscape of 
health regulation? 
The master thesis consists of the following documents; this summing up document, the 
attached FoKoM article, and the attached conference discussion paper. Analyses and 
facts are based on the three CAMbrella EU FP7 project reports describing the status of 
CAM regulation in 39 European countries and in the EU/EFTA/EEC.  
The objectives for the research are: to describe the status of CAM regulation in Europe 
with a patient safety focus, to highlight international theory dealing with patient safety, 
especially the role of regulation, and to analyse whether CAM regulation in Europe is in 
accordance with current theory dealing with risk governance and patient safety. 
3.2 Materials and Methods 
CAM can be regulated both within and outside the national public health care systems. It 
was therefore necessary to perform a combined search for both conventional and CAM 
health care regulation in each country. Materials and methods used for data collection 
are: documents and web sites, meetings and personal communication, and 
questionnaires. A literature search to identify official law documents and regulations was 
performed in national web sites/databases, as well as scientific and non-scientific journals 
and web sites. Searches were performed in the web sites/databases EUROPA and EUR-lex 
to identify European Union (EU) official legal documents. Personal visits, including 
meetings with the Ministries of Health (MoH), CAM practitioners and CAM associations 
were made to selected countries, CAM conferences and EU associations.  
It has been difficult to find appropriate methods to describe European CAM regulation in 
a uniform, European terminology where national legal traditions are understood and 
referred correctly. 
3.3 Results and Discussion 
Current risk governance and patient safety theory emphasize regulation as an important 
risk management instrument. We found no harmonization of, or comparable, CAM 
regulation between states, regions or in the EU, except for adapting legislation to EU 
directives on medicinal products.  
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The Directive 2011/24/EU on patients' rights in cross-border healthcare states that 
patients should be able to make informed treatment choices, and healthcare 
professionals are supposed to provide safe and effective treatments for European 
citizens. According to the FoKoM article and Birmingham conference paper, European 
patients may encounter substantial differences in regulation of and the professional 
background of apparently identical CAM providers and treatments both nationally and 
between countries.  
The regulation of CAM is so unclear that information given to patients on treatment 
efficacy and, -risk factors and their resulting risk perception are sub-optimal. National 
health authorities seem to regulate CAM based on insufficient basic information about 
risk factors, and regulation is consequently not balanced between risk reduction and risk 
tolerance. By analysing each step of the regulation process, we should find indications of 
how and if harmonized national and EU regulation of CAM may ensure increased patient 
safety and CAM treatment quality in Europe. 
Seen from a patient safety perspective, it is difficult to see a “CAM treatment security 
system” where both patients and authorities know the skills of the providers, and where 
the providers’ performance of the modalities is standardized. However, we do not have 
research evidence to claim that CAM patients are more exposed to unsafe treatment 
offered by non-medical providers than treatment offered by regulated health personnel. 
3.4 Conclusion and Recommendations 
CAM in Europe is not regulated in accordance with current theory dealing with risk 
governance, risk regulation and patient safety.  
European patients make their CAM treatment and provider choices based on insufficient 
and not trustworthy information. The diversity of European CAM providers’ skills and 
regulation may challenge patient safety. 
The above situation hampers CAM research, establishment of an efficient supervision 
system for health care providers, and reduces expected impacts of a governmental risk 
governance system on patient safety.  
Health authorities in Europe should raise attention to how CAM risk governance and CAM 
regulation could be embodied within the regulation of national health care services.  
The physiotherapy model of educational harmonization, research and modality 
standardization could be used as a template for the regulation of CAM treatments. 
Treatment standardization, CAM terminology clarifications and provider harmonization 
together with CAM research, will probably strengthen the safety of CAM patients in 
Europe. A Directive on CAM could be developed more or less in parallel with the 
Directives 2011/24/EC and 2005/36/EC.  
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7 Introduction 
Patient safety is a highly prioritized area within the provision of public and private health 
care services in both the European Union (EU) as a whole, member states, as well as in 
associated states. Runciman et al. defines patient safety as “the reduction of risk of 
unnecessary harm associated with healthcare to an acceptable minimum”(2). 
Risk assessment, risk evaluation and risk management, supplemented with risk 
communication and perception are important elements in risk governance irrespective of 
which societal field we analyze(3). It is essential in European risk governance of 
Complementary and Alternative Medicine (CAM) and patient safety, as in all societal 
fields, to have access to relevant knowledge and skills, and to establish a correct and 
updated decision platform. 
Risk governance giving preference to patient safety includes regulation as an important 
management tool. Regulation is a comprehensive expression for legislation (acts and 
statutory decisions), other normative activity to enable activities or restrict and prevent 
undesirable activities, and governmental supervision(4, 5). (See chapter 8.1). 
Regulations of importance for patient safety can cover requirements on provider 
education and training, provision of standardized and safe treatments, mandatory or 
voluntary professionals’ registers, supervision and professional title protection. Patients’ 
rights can cover correct information, safe treatment and provider choice, right to submit 
treatment claims, and reimbursement of treatment costs. (See attachment 15.5). 
In light of the focus on patient safety in Europe one would expect a strong coherence 
between European health care policy and the regulation of health care services. CAM is, 
in Europe, regulated either as conventional, complementary or alternative medicine, or 
not regulated at all. CAM is often not included in the health care services, and, as 
published in the FoKoM article (1), we hardly find any governmental regulatory or 
supervisory systems covering both conventional health care and CAM. 
The CAMbrella coordination project was funded by the 7th EU Framework Programme for 
Research and Technological Development (FP7) of the European Commission (EC), and 
was launched to improve the knowledge about CAM in Europe(6). The CAMbrella reports 
and the following research articles are meant to meet the information requirements of 
the estimated 100 million European citizens who are currently using CAM. The CAMbrella 
Work Package (WP) 2 report on the legal status and regulation of CAM may also impact 
European risk assessment on patient safety, health care regulation policy, and patients’ 
and providers’ risk perception. 
Complementary and alternative medicine (CAM) is the most commonly used term for 
treatments provided together with or instead of conventional medicine. Since there is no 
common international definition of conventional, complementary or alternative 
medicine, the following two definitions were used as a framework for the data collection 
in the CAMbrella project. 
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1) The CAMbrella consortium presented a pragmatic definition of CAM in their final 
key notes pamphlet(7): “CAM, as utilized by European citizens, represents a 
variety of different medical systems and therapies based on the knowledge, skills 
and practices derived from theories, philosophies and experiences used to 
maintain and improve health, as well as to prevent, diagnose, relieve or treat 
physical and mental illnesses. CAM therapies are mainly used outside 
conventional health care, but in many countries some therapies are being 
adopted or adapted by conventional health care.” 
2) The National Center for Complementary and Alternative Medicine (NCCAM) in 
USA defines CAM as “a group of diverse medical and health care systems, 
practices, and products that are not generally considered part of conventional 
medicine.” Conventional medicine (also called Western or allopathic medicine) is 
medicine as practiced by holders of M.D. (medical doctor and D.O. (doctor of 
osteopathic medicine) degrees and by allied health professionals, such as physical 
therapists, psychologists, and registered nurses.” ““Complementary medicine” 
refers to use of CAM together with conventional medicine, such as using 
acupuncture in addition to usual care to help lessen pain.” ““Alternative 
medicine” refers to use of CAM in place of conventional medicine.” ““Integrative 
medicine” combines treatments from conventional medicine and CAM for which 
there is some high-quality evidence of safety and effectiveness. It is also called 
integrated medicine”(8, 9). 
CAM regulation and training is different in each of the 39 European countries included in 
the CAMbrella WP2 survey. A NAFKAM research application forwarded to the EU FP7 
programme in 2012, states that  
“European citizens are increasingly seeking a broader spectrum of treatment 
modalities complementary to conventional medicine. This includes complementary 
and alternative medicine (CAM), also when offered outside their national health 
care system. CAM treatments are regulated very differently, if at all, in EU/EFTA 
countries. This could i) impede the availability of cross-border healthcare 
utilization; ii) impose a risk to patient safety.”(10). 
CAM modalities like acupuncture, anthroposophy, homeopathy, massage, naturopathy, 
osteopathy, and chiropractic are examples of modalities regulated as a conventional, 
alternative or complementary treatment in EU member states. 
7.1 Research question and objectives 
International and national CAM regulation is an important instrument to ensure a risk 
governance system safeguarding European citizens. Consequently an essential question 
is; 
What are the patient safety implications of the European disharmonious landscape of 
health regulation? 
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Discussions and theory in this summing up paper are built on the FoKoM article “Legal 
status and regulation of Complementary and Alternative Medicine in Europe“(1), the 
Birmingham conference discussion paper “CAM in Europe - a complex legal and regulative 
situation. Will harmonized EU-wide regulation strengthen CAM research and 
practice?(11), and empirical data collected in connection with the CAMbrella EU FP7 
project(6). This document will concentrate on patient safety and risk governance theory, 
emphasize methodological challenges, and widen the discussion. 
Objectives 
The objectives for the research are: 
1. To describe the status of CAM regulation in Europe with a patient safety focus. 
2. To highlight international theory dealing with patient safety, especially the role of 
regulation. 
3. To analyse whether CAM regulation in Europe is in accordance with current theory 
dealing with risk governance and patient safety. 
8 Theory 
CAM treatment in Europe is regulated as conventional, alternative or complementary 
treatments, or not regulated at all. This gives implications for patient safety. 
Figure 8.1 shows how the relationship between research, national regulation and 
European cross-border healthcare(12) accessibility could be connected. The model could 
be used as a basis for a theoretical discussion regarding patient safety linked to CAM 
regulation in Europe. 
The model (Figure 8.1) was developed by Fønnebø and Wiesener for the 2012 EU FP7 
proposal “CAMCrossEurope” with the title “The Patients’ Rights in Cross-border 
Healthcare – Directive 2011/24/EU. Interactions with research when national healthcare 
regulation varies”(10). 
 
 
Figure 8.1 Relationship between research, national regulation and cross-border healthcare accessibility. 
National legislation and regulation of health care services can be based on research 
and/or political, financial, traditional or cultural decisions. Important elements in these 
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considerations are established evidence whether and possibly how the treatments have 
effect and are safe, providers’ skills and the organization of public health services. Patient 
safety aspects are included in most political decisions. Other factors like pressure from 
interest groups, economy, local traditions, EU and regional regulations etc. may also 
influence national regulation. 
In 2005 The Institute of Medicine of the National Academies launched a report on CAM in 
USA. They stated that “decisions about the use of specific CAM therapies should primarily 
depend on whether they have been shown to be safe and effective”(13). The report’s core 
message was: 
 “The committee recommends that the same principles and standards of evidence of 
treatment effectiveness apply to all treatments, whether currently labelled as 
conventional medicine or CAM. Implementing this recommendation requires that 
investigators use and develop as necessary common methods, measures, and 
standards for the generation and interpretation of evidence necessary for making 
decisions about the use of CAM and conventional therapies”(13). 
8.1 Regulation and risk governance aspects 
Regulation is seen as an important instrument to ensure safe health care practice(11). 
Current governmental health control systems include terms like “risk”, “regulation” and 
“supervision”, but according to Lindøe et al. (14) there is no international harmonization 
of the meaning of these terms. Renn (3) defines risk as “a possibility that an undesirable 
state of reality (adverse effects) may occur as a result of natural events or human 
activities”. Connected to the patient safety classification discussion, Runciman et al.(2) 
define a patient safety incident as “an event or circumstance that could have resulted, or 
did result, in unnecessary harm to a patient”. Lindøe et al.(14) conclude that 
governmental risk governance must be balanced between risk reduction and risk 
tolerance, both based on information and knowledge of risk factors. 
Renn(3) describes “risk governance” as an interplay between governmental institutions, 
economic forces and civil society actors, such as non-governmental organizations 
(NGO’s). Risk analysis includes risk assessment, risk management and risk communication. 
In addition, according to Renn(3), risk governance includes consideration of legal, 
institutional, social and economic contexts. Renn’s “transparent model” (Figure 8.2) 
shows the interface between the above elements of risk assessment and management. 
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Figure 8.2 Ortwin Renn: Figure 1.5 The ‘transparent’ model (source adapted from Millstone et al, 2004) in Risk 
Governance; coping with uncertainty in a complex world(3) 
Renn’s ”transparent model” (Figure 8.2) and the “CAMCrossEurope” model (Figure 8.1) 
describe from different angles how risk assessment and research are important elements 
in governmental health regulation. 
With the above figures in mind, Renn’s model on levels of vertical and horizontal 
governance could be used as a framework when analysing regulative and patient risk 
aspects of CAM practices in a national, regional, European and global perspective.  Renn 
defines the horizontal level of governance with relevant actors and the vertical levels 
which execute decision-making processes within a defined geographical area (Figure 
8.3)(3). 
 
 
Figure 8.3 Ortwin Renn: Coping with Uncertainty in a Complex World. Figure 1.2 Levels of vertical and horizontal 
governance (Source: reproduced with permission from Bunting et al. 2007, p13) 
Legislation and regulation have different meanings. Legislation constitutes acts and 
secondary laws passed by a parliamentary/governmental body, and this legislation gives 
appropriate officials the authority to implement or enforce the laws(14). Primary 
regulations comply with rights, duties and competence, while penal provisions comply 
with penalties, compensations and disciplinary actions(15). According to Boe(15) 
international and national law are different in jurisdiction and content, and cannot easily 
be understood and compared by only referring to the written text. Regulation is a wider 
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term than legislation, used in English terminology as both acts, secondary acts and other 
official decisions made for restricting or enabling activities in the society(5). And to make 
this area even more complicated to understand, the rank order between acts, regulations 
and unwritten regulations may be quite clear in Norway, but can be completely different 
in other countries(15). 
Baldwin and Cave(5) describe “regulation”: 
• As a specific set of commands. 
• As deliberate state influence. 
• As all forms of social control or influence. 
Governments’ rationale for regulation has to be in pursuit of the public interests. Access 
to information may protect consumers, and regulation must produce socially desirable 
results. For example, medical costs covered by the state instead of the patient must meet 
regulatory constraints to avoid unwanted excessive consumption of medical services(5). 
C. Simpson states that informed patients make better healthcare decisions. Further, he 
claims that CAM interventions are not necessarily risk-free, but have an aura of safety, 
are inherently non-invasive, and “CAM patients rarely suffer life-threatening injury at the 
hands of their practitioners”(16). 
According to Renn(3) important elements in risk governance are the public perceptions of 
risk and effective risk communication. He emphasizes that human behaviour is primarily 
driven by risk perception and not by facts, and points out factors like “common-sense 
reasoning, personal experience, social communication and cultural traditions”.  We find 
these factors important when analysing why patients choose CAM treatments. 
8.2 Health authority perspectives 
Health authorities have regulation and supervision as risk governance tools, but 
regulatory bodies must also take patients’ free choice of treatments and providers into 
consideration(14). Governmental supervision is given authority through legislation(14), 
which in the 39 European countries will cover only CAM health personnel regulated by 
the national quality system for health services. 
“To Err Is Human: Building a Safer Health System” is part of a larger project examining the 
quality of health care in USA(17). The report from 2000 states that a strong regulatory 
component is critical in order to accomplish a basic level of safety for all who use the 
health care system. Risk governance strategies must be implemented inside health care 
organizations and in their external environment to improve patient safety. External 
environment includes regulation and legislative actions with any form of public policy or 
legal influence, such as licensing or the liability system. Defined minimum levels of 
capability or expected performance may be monitored by an official surveillance system, 
and corrective actions taken to maintain the minimum levels of performance(17). 
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Hood et al.(18) discuss in Figure 8.4 ways of comparing risk regulation regimes. In their 
table 2.1 they point out three important elements in any control system; information 
gathering, ways of setting standards and how to change individual and organizational 
behaviour. They emphasize how culture and values of life influence risk regulations and 
setting of safety standards. They also discuss that information quality is influenced by the 
fact that risk regulators vary their information gathering by active, reactive or interactive 
methods. 
 
 Control Components 
Information gathering Standard setting Behaviour modification 
Context: e.g., type and 
level of risk being 
tackled, nature of public 
or media attitudes, 
configuration of lobbies 
and organized interests 
Example: risks 
individuals can assess at 
low cost vs risks 
assessable only by 
professionals or at high 
cost 
Example: risks involving 
high stakes for 
organized groups vs 
risks with no lobby 
groups 
Example: risks where 
mass public opinion 
resists state control vs 
regulation ‘with the 
grain’ 
Content: e.g., regulatory 
stance, organizational 
structure, operating 
conventions and 
regulator attitudes 
Example: active vs 
passive information-
seeking by regulators 
Example: cost-benefit vs 
technical feasibility 
approaches to goal 
setting 
Example: price signals 
vs command 
approaches to control 
 
Figure 8.4  C Hood et al. table 2.1 Control components and regulatory regime content and context 
In the book Healthcare, Welfare and Law(19), Molven(20) underlines the importance of a 
clear definition of “health personnel” and “healthcare”. He refers to the Norwegian 
regulation of alternative medicine as legitimizing the right to practise outside regulated 
health care services. He states that a similar treatment provided by regulated health 
personnel within established health care services is not covered by the term “alternative 
medicine”. According to Molven(20), regulation will contribute to patient safety through 
acts regulating rights and duties of health personnel, with standards of authorization and 
accreditation, treatment performance and skills. In the same book, Braut(21) highlights 
that regulation of health professionals should be based on the principle of “sound 
professional standards” with statute laws defining educational and training standards, 
good professional practice and code of ethics. Both Molven(20) and Braut(21) argue that 
the above principles must be expressed through legislation like a “Health personnel Act” 
and through the regulation of health care services in for example a “Municipal Health 
Care Act” and a “Specialized Health Services Act”. 
Research evidence can be an important regulation tool when national and European 
health authorities consider regulation as shown in Figure 8.1. Recommendations from the 
Institute of Medicine in 2005 are to apply research methods used in conventional 
medicine to CAM(13). 
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8.3 EU perspective 
The Treaties of Rome and Lisbon(22) state clearly that the individual member state has 
the responsibility of “the definition of their health policy and for the organization and 
delivery of health services and medical care”(1). Medicinal products are not defined as a 
part of health policy, and can therefore be regulated at the EU level(23). Nevertheless, EU 
Directives and Regulations impact national health regulations directly or indirectly. Details 
of EU legal systems are described in the CAMbrella report no 3: “CAM regulations in 
EU/EFTA/EEA(24). 
Important EU directives influencing CAM regulations are: 
• Directive 2004/38/EC of 29 April 2004 on the right of citizens of the Union and their 
family members to move and reside freely within the territory of the Member 
States(25). 
• Regulation(EC) No 883/2004 of 29 April 2004 on the coordination of social security 
systems(26). 
• Directive 2005/36/EC of 7 September 2005 on the recognition of professional 
qualifications(27). 
• Directive 2011/24/EU of 9 March 2011, on the application of patients' rights in cross-
border healthcare(12). 
• Directive 2001/83/EC of the European Parliament and of the Council of 6 November 
2001 on the Community code relating to medicinal products for human use(28). 
• Directive 2004/24/EC of the European Parliament and of the Council of 31 March 
2004 amending, as regards traditional herbal medicinal products, Directive 
2001/83/EC on the Community code relating to medicinal products for human 
use(29). 
• DIRECTIVE 2004/27/EC of the European Parliament and of the Council of 31 March 
2004 amending Directive 2001/83/EC on the Community code relating to medicinal 
products for human use (Text with EEA relevance)(30). 
When introducing the Patient Rights in Cross-border Healthcare Directive(12) the Council 
assumes that “safe and high-quality healthcare” is in place when stating that there 
“is a set of operating principles that are shared by health systems throughout the 
Union. Those operating principles are necessary to ensure patients’ trust in cross-
border healthcare, which is necessary for achieving patient mobility as well as a 
high level of health protection”.  
Conventional healthcare is regulated quite similarly across Europe, and core health 
professionals are defined as "Sectorial professions" benefiting from automatic recognition 
on the basis of harmonization of minimum training conditions (doctors, nurses, midwives, 
pharmacists and dentists)(27). 
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A profession is considered regulated when access to it and the exercise of it are subject to 
the acquisition of a specific professional qualification, and an important legal basis for 
free movement of professionals in Europe is the Directive 2005/36/EC on the recognition 
of professional qualifications(24, 27). Even if health professionals to an extent are 
regulated by EU law, national legislation in the home state or the state of affiliation is 
most important when professionals cross borders in Europe(31). 
The European Commission database of regulated professions in the EU is covered by 
Directive 2005/36/EC(27). Chapter I of Title III of the directive sets out the general system 
for the recognition of documentation of training for the purpose of establishment in the 
host country(32).  
“The database includes among others the professions falling under the "General 
System" of mutual recognition of professional qualifications and the "Sectorial 
professions" benefiting from automatic recognition on the basis of harmonization 
of minimum training conditions: doctors, nurses, midwives, pharmacists, dentists, 
veterinary surgeons and architects”(32). 
Fisher stated in 1994 that a direct comparison of practitioners between countries, even 
within the European Union, are impossible because of varying legal situations(33). 
Disharmonized EU-legislation was emphasized by Wiesener and Fønnebø(11) when 
stating that “The established monitoring systems with regard to adverse reactions is 
mainly tailored to pharmaceutical drugs, and CAM supplements are therefore monitored 
for safety in a very rudimentary way”. Fønnebø et al.(34) suggested a five-phase strategy 
for assessing CAM: 
1. Context, paradigms, philosophical understanding and utilization. 
2. Safety status. 
3. Comparative effectiveness. 
4. Component efficacy. 
5. Biological mechanisms. 
The above strategy should generate evidence relevant for clinical practice, acknowledging 
an unclear distinction between conventional and non-conventional medicine and absence 
of regulatory gatekeepers for CAM(34). 
Disharmonized regulation of CAM in Europe - implications for patient safety Page 20 
 
9 Materials and Methods 
Data dealing with legislation and regulation of CAM and CAM medicinal products were 
collected from the EU and 39 European countries, of these 31 EU/EFTA member and 8 
associated states1(1, 35). 
The attached FoKoM article “Legal status and regulation of CAM in Europe”(1), and the 
Birmingham conference discussion paper “CAM in Europe - a complex legal and 
regulative situation. Will harmonized EU-wide regulation strengthen CAM research and 
practice?”(11) are based on empirical data collected for the EU FP7-HEALTH-2009, GA 
No.241951- CAMbrella project(36). This work was mainly done by S Wiesener on behalf of 
NAFKAM and the CAMbrella Work Package 2 (WP2) group. 
The three CAMbrella WP2 reports and the FoKoM article show legislation and regulation 
in force. Data used in the article are collected in the period March 2010 to June 2012. 
We were looking for: 
• General information about how each country is legally linked to the European Union 
and the Council of Europe. 
• The legal and regulatory status of CAM and CAM practices. 
• The governmental supervision of CAM practices. 
• The reimbursement status of CAM practices and medicinal products. 
• The regulation of the following modalities: acupuncture, anthroposophic medicine, 
ayurvedic medicine, chiropractic, herbal medicine/phytotherapy, homeopathy, 
massage, naprapathy, naturopathy, neural therapy, osteopathy, traditional Chinese 
medicine (TCM), other treatments if important for the specific country. 
• Physiotherapy is a recognized health profession in 38 of 39 European countries, and 
has similarities to CAM modalities like manual therapies, osteopathy, chiropractic and 
others. The regulation of physiotherapy was therefore included in our survey, and 
also included in the discussion on how the regulation of a CAM modality may be 
harmonized in Europe. 
9.1 Materials 
Materials used for data collection are: 
• Published documents. 
• Web sites. 
• Meetings. 
• Personal communication (emails, notes). 
                                                     
1 Croatia applied for EU membership in 2003. On 9 December 2011 leaders from the EU and Croatia signed 
the accession treaty. The country will become the 28th EU member country on 1 July 2013. 
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• Questionnaires. 
Initially a template was made for the description of each country (attached template 
example: The description of Romania). 
The following reports and book was used as a starting point for fact finding about the 
legal situation of CAM in Europe: 
• Stefano Maddalena: Alternative medicines: on the way towards integration?; A 
comparative legal analysis in Western countries, dated 2005(37). 
• The World Health Organization (WHO): Legal Status of Traditional Medicine and 
Complementary/Alternative Medicine : A Worldwide Review [database on the 
Internet]. Dated 2001(38). 
• The NAFKAM/Gerd Ersdal- EU report entitled "How are European patients 
safeguarded when using complementary and alternative medicine (CAM) jurisdiction, 
supervision and reimbursement status in the EEA area (EU and EFTA) and Switzerland" 
published by NAFKAM in 2005(39). 
• The World Health Organization (WHO): National policy on traditional medicine and 
regulation of herbal medicines: Report of a WHO global survey. Dated 2005(40). 
• WHO Regional Office for Europe, on behalf of the European Observatory on Health 
Systems and Policies: Health Systems in Transition:The Netherlands: Health system 
review, published 2010(41). (Remark: one survey for each country- this is one 
example). 
The following reports/Web pages published by CAM associations in Europe were found 
useful for fact-finding of CAM regulations in Europe: 
• ECHAMP  (European Coalition on Homeopathic and Anthroposophic Medicinal 
Products E.E.I.G): Homeopathic and Anthroposophic Medicine: Facts and Figures, 
published 2007(42). An updated third edition was published in 2011(43). 
• ECCH (European Council for Classical Homeopathy): The Legal Situation for the 
Practice of Homeopathy in Europe; Revised Edition 2009(44). An updated edition was 
published in 2010 and revised in 2011(45). 
• ECH (European Committee for Homeopathy): Web page: ECH in European Countries. 
Continuously updated(46). 
• CAMDOC (Alliance ECH ECPM ICMART and IVAA): The regulatory status of 
Complementary and Alternative Medicine for medical doctors in Europe. Published in 
2010(47). 
The “CAMbrella population-based systematic literature review protocol Version 1.5” 
was developed by WP7 for use in the CAMbrella consortium (attached). The protocol was 
used for a systematic search in the EU/EFTA, national legal health systems and health 
research databases (attached). 
Disharmonized regulation of CAM in Europe - implications for patient safety Page 22 
 
An adjusted version of the template for the description of each country was used in 
telephone conferences, emails, meetings and country visits (Template for country emails 
and telephone conferences) (attached). 
Meetings/CAM conferences were attended in: 
• Bologna:  CAMbrella Midterm Meeting, March 23-25, 2011. 
• Birmingham: An international and interdisciplinary conference - 5 May 2011, 
Hornton Grange, University of Birmingham, UK. Regulation and Professionalization in 
Complementary and Alternative Medicine: historical perspectives and contemporary 
concerns. Conference discussion paper forwarded (attached)(11) and S Wiesener 
attended as keynote speaker. 
• Berlin:  4th European Congress for Integrative Medicine and CAMbrella meeting 7 - 
8 October 2011. 
• Stockholm:  CAMbrella Meeting, 9 - 11 May, 2012. 
• Tromsø:  WHO Meeting at NAFKAM. Global strategy for Traditional Medicine (TM) 
and analysis of WHO global questionnaires on regulation. 
• Brussels:  CAMbrella Final Conference 29 November 2012. 
Personal visits were made to the following 4 countries: 
• Bosnia & Herzegovina (Federation of Bosnia and Herzegovina (FBiH) (Banja Luka) and 
Republika Srpska (RS) (Sarajevo)). 
• The Czech Republic (Prague). 
• Hungary (Budapest). 
• Montenegro (Podgorica and Igalo). 
Meetings were arranged with the Ministries of Health (MoH), national medicines 
agencies and CAM practitioners to collect information and confirm findings. Semi-
structured interviews and other personal communication followed the attached template 
“Interview and description for each country and treatment”. 
The “Questionnaire about the status of CAM therapies” (“CAMbrella” Project, EU FP7) 
Example: Romania)(48) (attached) was designed and a survey organized in 2010 by the 
CAMbrella WP2 representative at the Ministry of Health/the Pecsi Tudomanyegyetem – 
University of Pécs (Hungary) (PTE). CAM providers and MoH representatives from the 
following countries returned questionnaires: Greece, the Czech Republic, Hungary, 
Romania, Turkey and Slovakia. 
Some information could be extracted from the CAMbrella WP1 designed questionnaire 
from 2010 “Questionnaire definition and terminology of CAM and Legal status of CAM”. 
Example: Portugal (attached) (49). 
A visit was made in March 2010 to the European Union offices and NGO bodies in 
Brussels, and meetings were held with: 
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• Counsellor for health and food safety at the Mission of Norway to the EU. 
• The European Commission Central Library. 
• IVAA (International Federation of Anthroposophic Medical Associations) and ICMART 
(International Council of Medical Acupuncture and Related Techniques) - EU Liaison 
Office. 
• AESGP (The Association of the European Self-Medication Industry). 
9.2 Methods 
9.2.1 Surveys 
The work was initialized by a literature and web search for surveys performed on CAM 
legislation and regulation in the last decade (dated from 2000 – 2011). Information found 
in these reports and books was used as a starting point for fact finding about the legal 
situation of CAM in Europe. 
A number of other surveys similar to those mentioned under 9.1 were reviewed. Most of 
them referred to the above-mentioned documents or did not add facts of interest. 
9.2.2 CAM associations 
We searched in web pages and databases for material published by European and 
national associations representing the different CAM modalities included in our survey. 
These associations have generated surveys, publications and web pages showing the 
regulatory situation of CAM in Europe. Representatives of the CAM associations 
forwarded published surveys, national contact information, and links to web sites and 
databases. Fact discussions and rechecks were done in collaboration with the CAM 
associations. 
9.2.3 Literature search 
 A literature search to identify official law documents was performed in national web 
sites/databases, and scientific and non-scientific journals and web sites. We searched for 
official legal documents on the MoH and other governmental legal and official web sites 
in 39 countries. A search was performed for web sites representing most of the national 
and European CAM associations and professions included in the survey. We also 
performed a literature search in European CAM scientific journals, and in the EU/EFTA 
databases (EUROPA and EUR-lex). The CAM terminology and healthcare regulatory 
systems are so diverse that a systematic literature search gave few hits and limited 
information. A systematic literature search in EU/EFTA databases (EUROPA and EUR-lex) 
for regulation and legislation of CAM gave few hits, but search for specific, detailed 
information gave some results. 
During the data collection and analysing process it also became clear that conventional 
health care regulation has a strong impact on CAM. The search results became more 
successful when regulation of conventional health care was included. 
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9.2.4 Personal communication, visits and conferences 
Communication with the Ministries of Health, Law or Education, national medicinal 
agencies, other governmental representatives, members of national and European CAM 
associations/coalitions and CAMbrella members and stakeholders was performed with 
the help of emails and telephone conferences. New contacts and information were 
gained in meetings/CAM conferences in Europe. 
Personal visits, including meetings with the Ministries of Health (MoH) and CAM 
practitioners were made to four countries (see 9.1). These countries were selected on the 
basis of a need to double-check published information and to collect information on 
countries where information was not easily accessible. 
The CAM regulatory situation in each country is unclear. Therefore, in order to gain 
information from different interest groups, data was collected from bureaucrats, 
politicians, medical professionals and CAM providers. A few times health authorities were 
asked to verify the situation described for their specific country. 
Interviews and other personal communication were semi-structured. Questions became 
more direct and specified as the work progressed, and information was compared to data 
collected from other sources and for other countries. In many cases data had to be 
rechecked with the informants. 
9.2.5 Questionnaires 
One questionnaire survey was organized in 2010 by the CAMbrella WP2 representative in 
Hungary to gain information from countries in the eastern part of Europe(48). Six 
countries representing both EU member states and candidate countries returned the 
questionnaire. 
A CAMbrella WP1 designed questionnaire from 2010 included a few questions on CAM 
legislation(49). The answers were of low quality, and questionnaires from very few 
countries were forwarded to us. The information was used to give direction for further 
research. 
A WHO Global Survey questionnaire was disseminated in 2011. It was based on the global 
survey “National policy on traditional medicine and regulation of herbal medicines” 
launched in 2005 (with data collected in 2001)(40). WHO denied our request to get copies 
of the returned questionnaires. However, in meetings with the MoH in two of the 
countries visited, we saw that their answers on the questionnaire and response given 
directly to us in the meeting differed for some of the questions. Based on information 
given in the WHO questionnaires we discussed these facts with the country officials. 
9.2.6 The European Union (EU) 
Searches were performed in the web sites/databases EUROPA and EUR-lex to identify 
European Union official legal documents. To address CAM-related legislation in the EU, 
both the EU legislation that influences the member states’ national health legislation and 
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various aspects of EU regulation of conventional medicine were included. We searched 
for EU Directives and Regulations regarding CAM, and their EU/EFTA/EEA implications. 
Further, we searched for documents on other health issues, including legislation in 
progress, relevant for CAM. In addition data was collected from Decisions, News, 
Resolutions and relevant “Information” documents launched from the European 
Commission, the European Parliament and the Council of Europe. 
The Mission of Norway to the European Union provided information mainly on the 
EFTA/EEA legal connection to EU legislation and the new Cross-border Healthcare 
Directive 2011/24/EU(12). The European Union Commission Library assisted in searching 
for documents. AESGP provided information about the EU regulation of medicinal 
products(24). 
9.2.7 Translation from national language to English 
Legislation and regulation is written in the national language in each of the 39 countries. 
Few of the documents have an official translation to English. Information in the national 
languages was either translated to English in an official version by the MOH or CAM 
association contacts, or native contacts helped to find the information and forwarded an 
English version. In some cases Google Translate gave adequate information for further 
search, either on web sites or by forwarding references or documents to native contacts 
who extracted information in English. References are given to the original documents in 
the original language if there is no official translation of the document. In some cases we 
forwarded the English version of country descriptions to national, governmental 
representatives and/or CAM associations and providers to be confirmed. This was a 
continuous quality process until the delivery of the CAMbrella reports. 
9.3 Methodological considerations and challenges 
It has been difficult to find appropriate methods to describe European CAM legislation in 
a “uniform, European legal terminology” where national legal traditions are understood 
and referred correctly. CAM terminology, and the interaction between conventional 
medicine and CAM, in regulation, health care systems and research vary widely in the 39 
countries and the EU. Thus, it was necessary to make a comprehensive search for matters 
that could influence CAM in national and EU/EFTA legislation. The report intended to 
describe facts on legislation and regulation in force at the primary and secondary legal 
level. Since CAM can be regulated both within and outside the national public health care 
systems, it was necessary to perform a combined search for conventional and CAM health 
care regulation in each country. 
Within the same country and even within the same institution informants gave a 
substantial diversity of answers to similar questions. It was therefore essential to 
communicate with representatives from different environments in the EU and the 39 
European states. Most of the trustworthy information was found by using different 
search methods, and then compare and verify data by rechecking the information. Even 
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information given from the Ministries of Health (MoH) had to be rechecked. The attached 
“template for interviews and descriptions for each country and treatment”, shows the 
definitions used in interviews and data collection. The interview situation differed widely. 
In most countries it was necessary to start with a discussion and clarification on 
terminology and definitions of CAM before establishing facts about legislation. No 
national legislation were directly comparable to other countries, so information had to be 
confirmed repeatedly and from different angles also during the interviews. Our 
experiences correspond with Boe’s findings, referred to in chapter 8.1., that international 
law is difficult to compare and understand. 
A search for surveys can be efficient and time-saving for data collection. Some of the 
surveys were based on questionnaires, others on combined methods. However, it was 
impossible to completely trust the data. CAM and regulatory definitions and terminology 
varied, data included or excluded differed between the studies, and regulative definitions 
were unlike those used in the CAMbrella project. Data collected turned out to be wrong 
or inaccurate, and relevant data was often missing. Legislation is an on-going process with 
continuous changes in most countries. The information extracted from the surveys was 
not updated to the situation in 2010-2012. The Stefano Maddalena book from 2005(37) is 
based on data collected in 1999. Most of the surveys referred to the Maddalena book or 
to surveys from 2005 or earlier, and most surveys referred to each other. The surveys 
published by the CAM associations from 2005 up to 2011 were also based on and referred 
to findings in surveys from before 2005. The number of countries included in each survey 
differed. Many of the 39 countries included in the CAMbrella work were not included in 
these surveys. In other cases information was missing for some countries even if they 
were included in the survey. References to laws and regulations turned out in many cases 
to be incorrect. As a consequence much of the data in the surveys were found to be too 
old, wrong or inaccurate. However, the data found was used for further search and was 
also compared to information found using other methods. 
As discussed by Lindøe et al.(14) the words “regulation” and “legislation” have different 
meaning depending on whom you ask, and we struggled to find a way to describe facts as 
precisely as possible. In our work we used the word “regulation” as a comprehensive 
term for all forms of official regulation and acts, while the word “legislation” is used when 
referring directly to laws. 
The “fact” situation in each country was described by including every official document at 
the primary and secondary legal level containing anything about CAM or the CAM 
modalities included in our survey. Each country was described by using one template, but 
national descriptions and references were developed in a narrative form. In the FoKoM 
article we referred to data that we found comparable. However, figures 3 and 4 on 
Homeopathy in the article(1) show how difficult it is to find a valid method to compare 
CAM regulation in Europe. 
Disharmonized regulation of CAM in Europe - implications for patient safety Page 27 
 
Questionnaires are efficient for collecting comparable data from many informants. 
However, it was difficult to develop a questionnaire design that ensured trustworthy 
answers. We compared questionnaires returned to WHO in their “2012 questionnaire” 
with information provided to us on the same questions. We found several discrepancies 
when comparing information collected by these two methods. 
Systems and the cultural tradition of governmental regulation in states from the Eastern 
Europe differ in many aspects to the “old” European way of regulating healthcare services 
and providers. It was expected that the questionnaire developed only for use in the 
Eastern countries would ensure correct and comparable data. However, the 
questionnaire answers were not valid due to language challenges, different CAM 
terminology or regulatory differences between the states. The information was therefore 
only used for further research. Hardly any of the answers in the WP1 questionnaire were 
valid. 
Based on our experiences when studying the above questionnaires we found it of no 
value to develop a specific “CAMbrella” questionnaire for fact-finding of CAM regulation 
in the European countries. This method was therefore not used for further data 
collection. 
Legal documents on CAM regulation are usually not found in research databases, and 
most CAM research articles discuss aspects of CAM with few direct references to updated 
national legislation. Common expressions found were “osteopathy is regulated in NN 
country”, “only doctors may treat patients”, “health personnel may provide 
acupuncture”, or as found in the Criminal law in Croatia: “Whoever, lacking prescribed, 
professional qualifications, medically treats another or renders medical aid to such a 
person shall be punished by-..”. These expressions gave a starting point for further search 
on legal documents describing CAM treatments or providers. 
Since most legislation is written in the respective national languages, meanings and 
nuances may be lost in the translation process. For most of the countries the English 
phrasing of the legal and regulatory situation can be challenging. The legal regulation of 
CAM is often a controversial political matter, and one country preferred to present their 
own written description of their CAM situation. 
The CAMbrella advisory board represents European CAM associations. They used their 
comprehensive network in Europe to double-check information. 
It has been challenging to extract comparable data from the 3 CAMbrella reports for use 
in the attached FoKoM article(1). To my best knowledge data described in the article is 
trustworthy and updated. However, when describing the legal situation for CAM in 
Europe, one must be aware of and, if possible, highlight the definitions and terminology 
in use, and clearly describe which data that have been included and excluded in the 
discussions. 
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10 Results 
Legal systems regulating national health care services vary between the 39 European 
countries, and we found no two countries where national legislation or regulation of CAM 
was comparable. Even when CAM was regulated, the question “who are allowed to 
practise NN treatment?” was difficult to answer. An example of how difficult such 
interpretations could be is shown in the FoKoM article Fig. 4. “An overview of groups that 
can legally practice homeopathy in 39 European countries”(1). 
At the Birmingham conference in 2011(11) we presented that we had found two main 
approaches to CAM regulation; countries where all practice of CAM is regulated in some 
way or another, and countries that do not regulate the field at all or only regulate some 
of the CAM treatments. The distinction between those two approaches became more 
diffuse when we gathered more detailed information from each country, so in 
subsequent presentations we found more suitable ways of describing the status of CAM 
regulation in Europe. 
We found that the 12 new EU member states admitted in 2004 and 2007, as well as the 8 
candidate states(1, 35) had changed their health legislation to adjust to EU membership 
or application. However, we found no harmonization in legislation between states, 
regions or in the EU, except for adapting legislation to EU directives on medicinal 
products. 
10.1 Patient perspective 
We found the regulation of CAM in Europe so unclear that the information given to 
patients on treatment efficacy, risk factors and their following risk perception cannot be 
optimal. 
The task of CAMbrella WP3 was to identify the needs and attitudes of European citizens 
with regard to CAM. They found that “Citizens call for impartial, reliable and trustworthy 
information to support informed decision-making, and some citizens wish for greater 
support and involvement of biomedical healthcare professionals in facilitating their 
healthcare choices.”(50). 
Reimbursement of CAM treatment is mostly obtained only if provided within the 
conventional healthcare services, by a regulated health professional or if the CAM 
treatment is regulated. In most countries reimbursement is covered only if the patient 
has private insurance. Patients may receive CAM in one country, with treatment expenses 
reimbursed in their home country. However, the amount of expenses covered for each 
treatment depends on how CAM is regulated in both countries. 
A successful implementation of the directive on patients' rights in cross-border 
healthcare(12), makes it imperative to have an appropriate overview of the national CAM 
regulation in the EU member states. According to the directive patients should be able to 
make informed treatment choices and healthcare professionals are supposed to provide 
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safe and effective treatments for European citizens. According to the FoKoM article(1) 
and Birmingham conference paper(11) European patients may encounter substantial 
differences in regulation of and the professional background of apparently identical CAM 
providers and treatments both nationally and between countries(1). “This heterogeneous 
situation influences CAM patients’ rights, access and potential safety”(1), and patients 
seeking these treatments cannot make use of their cross-border rights if their own (state 
of affiliation) and the other country (member state of treatment) have not regulated the 
treatment similarly(10). 
10.2 Practitioner perspective 
Legislation on health professionals was found in all the countries included in the 
CAMbrella WP2 survey. We found acts like “Health professionals Act” and “Public Health 
Care Services Act” (named slightly different in each country). Requirement to practise 
according to “sound professional standards” was expressed with various terms, but was 
found in most of the acts and regulations. CAM professionals were included in the acts in 
some countries and not at all in others. Each country regulates health professionals and 
CAM providers differently, and we found no comparable list of health professions 
included in these acts. Consequently, in the reports we described if and how the 
respective CAM profession was regulated. 
When reviewing the regulation of health professionals we looked for standards for 
educational level and training (including ECTS standards), registration in the EU health 
professionals’ database, protected title, statutory or voluntary registers, and code of 
ethics, licences and authorizations. Health professions and treatments were regulated by 
national general or specific law, or regulation was delegated to associations or 
government offices. 
CAM is in some European countries provided by regulated healthcare professionals and 
thereby clearly covered by the Directive 2011/24/EC on the application of patients' rights 
in cross-border healthcare(12) and the Directive2005/36/EC on the recognition of 
professional qualifications(27). The same CAM practice unregulated or regulated with 
different requirements in another country would not be covered by these directives(36). 
Few of the EU member states have CAM professions registered in the EU regulated 
professions database (see examples in Figure 10.1, Figure 10.2). We have not found that 
harmonization of training for CAM professionals constitutes a special focus in the 
Directive 2005/36/EC on professional qualifications(27) or in national health regulation. 
Several member states only permit doctors or other health professionals to practise CAM. 
Other member states have introduced legislation regulating CAM practice by non-licensed 
health practitioners. 
European countries have established national health supervision systems for regulated 
health professionals (doctors, nurses, midwifes etc.), but this system will only apply to 
CAM practitioners regulated as health personnel(11). In some countries the follow-up of 
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CAM regulation has been delegated to medical or CAM associations. This system could 
cover the authorization of CAM providers, education and training, licences and statutory 
or voluntary registers. (For example Brønnøysundregistret in Norway(51, 52)). In a few 
countries with CAM regulation, provider supervision may be performed through those 
associations. 
10.3 Chiropractic and physiotherapy regulation in 39 European countries 
10.3.1 Chiropractic 
Chiropractic is a treatment and profession that, if regulated at all, is regulated in Europe 
as conventional, alternative or complementary. Chiropractor is recognized and regulated 
as a conventional health profession in 16 of the 39 countries. 10 of these countries have 
also registered chiropractor in the EU regulated professions database. Even so, 
educational and professional regulation differs between these countries. In 10 countries 
there is regulation on chiropractic treatment, but not a regulated profession called 
chiropractor. 
In 13 countries we found no specific regulation of chiropractic, but the treatment may be 
regulated through CAM general legislation or conventional health legislation. Some 
countries regulate chiropractic and similar therapies as “manual therapies”, and we found 
regulation describing that other professionals may use chiropractic treatment methods, 
for example physiotherapists. 
We found few comparable European regulation standards for the protection of the 
chiropractic title, curriculum and training, professional exercise or code of ethics. From 
2012 the European chiropractors’ union together with the European committee for 
standardization is preparing European standard requirements and recommendations for 
healthcare services provided by chiropractors. 
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Figure 10.1 Chiropractic regulation in Europe 
 
10.3.2 Physiotherapy 
Physiotherapy is recognized as a conventional regulated health profession in 38 of the 39 
countries we have described, and 29 of 31 EU/EEA members have registered the 
profession in the EU regulated professions’ database (Figure 10.2). Physiotherapy has 
been harmonized according to the “General system” of mutual recognition of 
professional qualifications according to the professionals directive(27). With collaboration 
through The World Confederation for Physical Therapy (WCPT) Europe, together with the 
European Physiotherapy Associations, physiotherapists across Europe hold the same 
professional standards, and patients are ensured that they will encounter professionals 
with similar background and experience. 
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Figure 10.2 Physiotherapy regulation in Europe 
11 Discussion 
We found it challenging to establish a correct, comparable system for the description of 
CAM regulation in Europe. None of the 39 European countries’ health care legislation or 
regulation was comparable directly with other countries since CAM, conventional 
treatments, providers, health professions, education, supervision, reimbursement, 
authorization and licences are defined and regulated differently. It was not possible to 
use one specific definition of CAM or “regulation” when gathering data from the 39 
countries.  We solved those challenges by describing facts found for each country 
showing how they had defined and regulated CAM in general and each of the 13 chosen 
treatments. 
Consequences of disharmonized CAM regulations for patients, providers and research are 
discussed in the FoKoM article(1) and in the conference paper(11). An important question 
is if and how more harmonized regulation of CAM in Europe will influence patient safety. 
Are adverse events more common in CAM treatment than in conventional treatment 
provided by regulated health personnel? As stated by Stub et al.(53) “The Medical 
Homeopaths used the view of both professions and always looked for red flag situations 
in the consultation room”, and further her informants expressed that “A more 
comprehensive toolkit gave the medical homeopaths a feeling of professionalism”, and 
“They combined knowledge from two treatment systems which may have advantages for 
the patient”. 
The homeopath example leads to several questions. Medical homeopaths have both a 
medical education and homeopathic training. It seems reasonable to claim that this will 
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strengthen their homeopathic practice and thereby the patient safety. But what happens 
when the medical doctor has less homeopathic training? Will he/she provide a safer 
treatment than a non-medical homeopath with comprehensive homeopathic training? 
Perhaps the treatment is safe, but what is the quality of the homeopathic treatment? On 
the other hand, the non-medical homeopath will probably provide a safe homeopathic 
treatment for most of the patients, but we do not know if his/her medical competence 
will cope with adverse events in the same way as a medically trained provider. 
Regulation ensuring that homeopaths have a minimum level of medical training may 
meet some of the above challenges. For example, to be a member of Norske 
Homeopaters Landsforbund (NHL) and registered in The Brønnøysund Register you need 
120 ECTS credits of medical training added to the homeopathic training. If these training 
standards were equal all over Europe, all homeopaths would probably know when to stop 
their own treatment and refer to conventional treatment. Similar thinking is possible for 
all CAM modalities. 
The decision platform for CAM regulation in Europe is unclear. Regulation of conventional 
health care modalities and providers seems mainly to be based on standardization and 
research, and conventional health care services in the European countries are to a great 
extent comparable, even if the legislative expression of the normative fundament may 
vary considerably. The national governmental decision basis and consequences for 
European CAM regulation both need to be analysed to fulfil the EU Commission’s 
intention “to ensure patients’ trust in cross-border healthcare, which is necessary for 
achieving patient mobility as well as a high level of health protection”(12). The 
“CAMCrossEurope” model (Figure 8.1) could be a template for this work. If the model in 
Figure 8.1 is valid, by analysing each step of the regulation process, we should find 
indications how and if harmonized national and EU regulation on CAM may ensure 
increased patient safety and ensure CAM treatment quality in Europe. 
It is difficult to describe the connection between patient safety and legal regulation of 
complementary and alternative medicine (CAM) in Europe. The European and national 
heterogeneous regulation of CAM providers and treatments may be unsafe for the 
patients, but many consider CAM as mostly “well-being” treatments with few patient 
safety challenges. It is, however, a problem that European citizens do not make their 
treatment choices on an informed platform, where they can balance risk facts and their 
own risk perception with risk tolerance. National health authorities seem to regulate CAM 
based on insufficient basic information about risk factors, and regulation is consequently 
not balanced between risk reduction and risk tolerance. By this absence of regulation 
standards, Renn’s (3) recommendations for efficient risk governance and management 
can hardly be followed. 
The C Hood et al. model(18) (Figure 8.4) underlines the importance of comparable 
information gathering in risk regulation. As discussed in the material and methods 
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chapter, as well as shown in results, this element is a substantial challenge both in 
national and international CAM regulation. As concluded in the CAMbrella WP3 
report(50) patients make their decisions in an unreliable and not trustworthy 
environment which makes it impossible to fulfil the Cross-border Directive(12) intentions 
that patients shall be able to make informed treatment choices when crossing borders in 
Europe. 
Even within many European countries it is difficult for patients, providers and authorities 
to make informed decisions. Further, many CAM providers are not regulated as health 
personnel, and consequently not covered by governmental supervision. This limits 
patients’ compensation claim rights, and the possibility of complaints and reimbursement 
of treatment costs. 
In Europe there are more than 150.000 registered medical doctors with an additional 
CAM certification and more than 180.000 registered and certified non-medical CAM 
practitioners - however, regulation of and education in CAM is different in all the 39 
European countries. Reflecting this fact, Professor Wolfgang Weidenhammer said at the 
CAMbrella final conference in Brussels in November 2012: “Health professionals must 
give safety and security to their patients and clients. The current EU regulation and 
education chaos for CAM provision makes this an impossible task.”(54). The European 
governments’ rationale for regulation or non-regulation of CAM is diffuse, and it seems 
like “the public interests” mentioned by Baldwin and Cave(5) is not clearly given priority. 
The CAMbrella WP2 results are supported by the CAMbrella WP5 findings. According to 
their conclusion we find that Fisher’s statement from 1994(33) is still valid in 2012; 
 “CAM provision in the EU is maintained by approximately 305,000 registered 
medical doctors and non-medical practitioners, with a huge variability in its 
national regulatory management, which makes any direct comparison across the 
EU almost impossible. Harmonisation of legal status, teaching and certification of 
expertise for therapists would be of enormous value and should be 
developed.”(55). 
It is difficult to describe the legal status and regulation of CAM in Europe when there are 
no common definitions and terminology of conventional, complementary and alternative 
medicine. More important, the differences in CAM regulation make it challenging to 
ensure safe practice of CAM across boundaries in the EU/EEA area(11). A successful 
implementation of the directive 2011/24/EU on patients' rights in cross-border 
healthcare(12), makes it imperative to generate a correct overview of national CAM 
regulation in the EU member states. European health authorities need to discuss how the 
safety of CAM patients can be safeguarded under the current regulatory system(11). 
Complementing national legislation, Directive 2005/36/EC(27) supports harmonized 
regulation of health personnel in all EU member states, and the principle of sound 
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professional standards for health professionals is to a great extent harmonized for 
regulated professions. However, hardly any of the CAM professions are included in those 
regulations, so practitioners and patients - crossing borders encounter a substantial 
variety of CAM practice and practitioners’ competence in Europe. As stated in the article, 
”this raises serious concerns with regard to the predictability, quality and safety of health 
care delivery to European citizens”(1). With the mutual recognition of medical doctors 
within the EU, some physicians could be well qualified for CAM treatments, while others, 
immigrating from countries with no mandatory or voluntary training in CAM in their 
medical curriculum, may be unqualified to practice CAM modalities. Safety aspects will 
accordingly be based on unclear standards of skills and medical knowledge for CAM 
practitioners in Europe. 
If we look into the regulation of chiropractic treatment in Europe it is natural to ask if 
there is more evidence–based research available in countries where chiropractic is 
regulated compared to countries with no regulation of chiropractic providers or 
treatment? Also, is it safer to receive chiropractic treatment in countries with regulation 
than in countries with no such regulation? Compared to the physiotherapy and 
homeopathy discussion it is fair to argue that harmonized standards with regard to 
medical and CAM education and training, combined with research, will ensure a higher 
level of safety for patients receiving CAM treatments. 
The successful development processes towards harmonized regulation and today’s 
mutual recognition of physiotherapists across Europe could be a potential framework for 
standardization of other CAM professions and treatments like chiropractic, massage, 
osteopathy, naprapathy and others. 
Directive 2011/24/EU on the application of patients’ rights in cross-border healthcare(12), 
stipulates that “Member States should facilitate cooperation between healthcare 
providers, purchasers and regulators of different Member States at national, regional or 
local level in order to ensure safe, high-quality and efficient cross-border healthcare”(12, 
31). When analysing CAM regulation in 39 European countries the FoKoM article 
concludes that it is important to encourage individual states within culturally similar 
regions to harmonize their CAM regulation(1). 
The fulfilment of the Institute of Medicine statement from 2005 about common evidence 
standards for CAM and conventional medicine will meet many challenges(13). Statements 
like “CAM is mostly well-being treatment” and others claiming that “CAM is safe and have 
few adverse effects” will probably influence how health authorities regulate CAM and 
patients’ choice of treatment. It seems like patients want to choose freely among 
conventional, complementary and alternative medicine, and CAM treatment is in many 
cases chosen when conventional medicine does not fulfil expected and wanted treatment 
effects. 
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European cross-border research on efficacy and effectiveness of CAM is severely 
hampered by the conglomerate of European regulation(1). A structured systematic 
literature review by the CAMbrella Deliverable 10: “ Roadmap for future research” in 
2012, supports the Institute of Medicine 2005 report(13) and states that “Most authors 
vote for the use of commonly accepted research methods to evaluate CAM”(56). Both 
reports point to severe methodological challenges for CAM research, but show a 
consensus that both qualitative and quantitative methods are valuable and that “a mixed 
methods approach is the most suitable for gathering conclusive knowledge about 
CAM.”(56). The CAMbrella WP4 reviewing CAM prevalence in Europa states that “A 
consistent definition of CAM, a core set of CAMs with country-specific variations and a 
standardized reporting strategy to enhance the accuracy of data pooling would improve 
reporting quality”(57). As discussed in chapter 9 (Materials and Methods) the 
methodological challenges found in all these CAMbrella articles are also experienced 
when collecting data for the WP2 report and for the WP2 FoKoM article. 
Supervison of CAM professionals is hampered by absence of legislation in the European 
countries. Consequently regulated health care personnel providing CAM, like doctors, 
nurses, midwives and others, are supervised, while non-medical (not regulated) providers 
of CAM will be excepted from the governmental supervision system. On the other hand, 
CAM training could be more comprehensive for providers not holding a regulated health 
profession. In some countries CAM treatment is restricted to medical doctors, in others 
there are no official provider restrictions in national health regulation. The official control 
system includes or excludes CAM providers depending on regulation of other professional 
skills than those needed for the specific CAM treatment. Unregulated CAM providers can 
be prosecuted according to Criminal Law. 
Hood et al. (18) underline the importance of comparable standards and information in 
risk regulation. We found few standards in European CAM regulation, and governmental 
risk assessment for CAM is hardly based on informed, comparable safety information. 
However, the European health professionals’ associations have started many processes to 
achieve more professional standardization. Good examples are the associations 
representing physiotherapists, chiropractors and homeopaths. Patient safety and CAM 
risk governance could be improved by supporting the CAM associations with international 
standards for CAM health care services and CAM training developed by health authorities 
in Europe. 
Seen from a patient safety perspective, being aware of the CAM regulation found in 39 
countries, it is difficult to see a “CAM treatment security system” where both patients and 
authorities know the skills of the providers, and where the providers’ performance and 
the content of the modalities is standardized. However, we do not have research 
evidence in our project to claim that CAM patients are more exposed to unsafe treatment 
offered by non-medical providers than treatment offered by regulated health personnel. 
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To ensure safe health care practice, current risk governance and patient safety theory 
emphasize the importance of legislation and regulation as risk management instruments. 
A review of CAM regulation in 39 European countries, with a patient safety focus, shows 
that European CAM regulation is disharmonious and unclear. With this background health 
authorities in Europe should raise attention to how CAM risk governance and CAM 
regulation could be embodied within the regulation of national health care services. 
12 Conclusion and Recommendations 
12.1 Conclusion 
CAM in Europe is not regulated in accordance with current theory dealing with risk 
governance, risk regulation and patient safety. A review of the status of CAM regulation in 
39 European countries, with a patient safety focus, shows that European CAM regulation 
is diverse and unclear. Consequently, it is fair to claim that the disharmonious landscape 
of CAM regulation in itself may impact patient safety. 
European patients make their CAM treatment and provider choices based on insufficient 
and not trustworthy information. CAM terminology is not uniformly defined and 
treatment modalities are not standardized. 
CAM professionals can be medical doctors or other health professionals, with or without 
CAM training, or non-medical CAM providers with long or short CAM training. We found 
few mandatory or standardized CAM training programmes and professionals’ registers. 
This diversity of European CAM providers’ skills and regulation may challenge patient 
safety. 
The above situation hampers CAM research, establishment of an efficient supervision 
system for health care providers, and reduces expected impacts of a governmental risk 
governance system on patient safety. 
12.2 Recommendations 
Regulation of CAM could be embodied within a risk governance system covering 
conventional, alternative and complementary health care services. Treatment 
standardization, CAM terminology clarifications and provider harmonization together 
with CAM research, will probably strengthen the safety of CAM patients in Europe. A 
Directive on CAM could be developed more or less in parallel with the Directives 
2011/24/EC(12) and 2005/36/EC(27). 
The physiotherapy model of educational harmonization, research and modality 
standardization could be used as a template for the regulation of other CAM treatments. 
Development towards European harmonized regulation of CAM would probably give 
patients, health care providers, researchers and governmental authorities a similar 
standardized, informed and safe decision platform. 
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13 Supplementary data 
13.1 Authors background 
I have a position as senior adviser at NAFKAM (The National Research Center in 
Complementary and Alternative Medicine), Faculty of Medicine, the University of Tromsø, 
Norway. The last 3 years I have been connected to the European Union (EU) - CAMbrella 
project (1), and the main work for Work Package 2 (WP2) “Legal status and regulations” 
has been carried out by me. The CAMbrella project consortium consists of 16 partner 
institutions from 12 European countries. Empirical data was collected from 39 countries 
and the EU/EFTA/EEA. The final delivery of 3 reports (with me as the first author of two) 
was forwarded to the EU on November 29, 2012. Two reports describe national 
regulation of CAM in 39 countries and in the EU/EFTA, and the third report describes 
regulation of CAM medicinal products in Europe.  The empirical data will be used for 
further research, including the FoKoM article(1) and this summing up document for the 
master thesis. 
13.2 Time table 
Data has been collected from May 2010 - May 2012. Quality check and updates were 
carried out during autumn 2012 until final delivery of the CAMbrella EU project late 
November 2012. 
13.3 Collaboration and scientific network 
I collaborate with researchers at NAFKAM and with the CAMbrella network in Europe. 
Patient safety is included in the strategy plans for future research at NAFKAM. NAFKAM is 
a collaborating centre with the World Health Organization (WHO). 
13.4 The master study modules 
This master thesis is the final module of the Master program: “Masterstudier i 
samfunnssikkerhet”- a collaboration study program between the Buskerud University 
College (HiBu), the University of Stavanger (UiS) and Nasjonalt utdanningssenter for 
samfunnssikkerhet og beredskap (NUSB) placed under the Norwegian Directorate for Civil 
Protection (DSB). In addition to this thesis, the master program has included the following 
study modules and my exam deliverables (available only in Norwegian): 
• Infrastructure and vulnerability (UiS MTS230): Hvorfor er distribusjonsdelen av 
kraftforsyningen i Norge ikke forberedt på å møte et fremtidig endret klima? (Why is 
the distribution of Norwegian power supply not prepared to meet future climate 
changes?). 
• Risk based management (UiS MTS140): Sort gull til besvær! Økt skipstrafikk - økt 
risiko? (Black Gold Challenges! Increased shipping – increased risk?). 
• Risk and societal safety (UiS MSA 115): Hvordan påvirker fragmentert ansvar og 
organisering norsk kystberedskap? (How do fragmented responsibility and 
organization influence Norwegian Coastal disaster and crisis management?). 
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• Disaster and Crisis Management (HiBu KAKRI100), module 1: FN’s 
Sikkerhetsresolusjon 1325. Kvinner, Fred og Sikkerhet. (The UN Security Council 
Resolution 1325 on women and peace and security). 
• Disaster and Crisis Management (HiBu KAKRI200), module 2: Hvordan påvirket den 
norsk-fiansierte opprustningen av Srilankesisk sykepleierutdanning post-tsunami 
rehabilitering I Batticaloa? (How did the Norwegian financed support of Srilankesisk 
nurse education influence post-tsunami rehabilitation in Batticaloa?). 
• Staff and Crisis management (HiBu STAKRI100): På hvilken måte påvirker moderne 
teknologi kriseledelse? (How is modern technology influencing crisis management?). 
• Philosophy of Science and Research Methods (UiT STV-3074): Utkast til 
forskningsdesign for empirisk masteroppgave. (A research design for an empiric 
master thesis). 
In all fields analyzed, from infrastructure and power supply to disaster planning, we 
conclude that harmonization of international and national regulation is an important risk 
management tool. 
The risk governance theory and societal safety aspects dealt with in the above 7 master 
program modules have been useful knowledge background when analyzing how 
regulation of CAM may influence patient safety in Europe. 
13.5 Personverneombudet NSD 
The project does not include information that should be reported to NSD. 
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Summary
Objective: The study aims to review the legal and regula-
tory status of complementary and alternative medicine 
(CAM) in the 27 European Union (EU) member states 
and 12 associated states, and at the EU/European Eco-
nomic Association (EEA) level. Methods: Contact was es-
tablished with national Ministries of Health, Law or Edu-
cation, members of national and European CAM associa-
tions, and CAMbrella partners. A literature search was 
performed in governmental and scientific/non-scientific 
websites as well as the EUROPA and EUR-lex websites/
databases to identify documents describing national 
CAM regulation and official EU law documents. Results: 
The 39 nations have all structured legislation and regula-
tion differently: 17 have a general CAM legislation, 11 of 
these have a specific CAM law, and 6 have sections on 
CAM included in their general healthcare laws. Some 
countries only regulate specific CAM treatments. CAM 
medicinal products are subject to the same market au-
thorization procedures as other medicinal products with 
the possible exception of documentation of efficacy. The 
directives, regulations and resolutions in the EU that 
may influence the professional practice of CAM will also 
affect the conditions under which patients are receiving 
CAM treatment(s) in Europe. Conclusion: There is an 
 extraordinary diversity with regard to the regulation of 
CAM practice, but not CAM medicinal products. This will 
influence patients, practitioners and researchers when 
crossing European borders. Voluntary harmonization is 
possible within current legislation. Individual states 
within culturally similar regions should harmonize their 
CAM legislation and regulation. This can probably safe-
guard against inadequately justified over- or underregu-
lation at the national level.
Introduction
The European Parliament [1] and the Parliamentary Assem-
bly of the Council of Europe [2] have both passed resolutions 
recommending a stronger harmonization of, what they call, 
non-conventional medicine in Europe.
The European Union (EU) has, however, repeatedly con-
firmed that it is up to each member state to organize and 
 regulate their healthcare system, and this will, of course, also 
apply to complementary and alternative medicine (CAM). 
Despite this confirmation, the recent Patients’ Rights in 
Cross-Border Healthcare Directive 2011/24/EU [3] and other 
directives indirectly encourage some degree of harmoniza-
tion. CAM professions can be registered in the European 
Commission (EC) database of regulated professions, and 
 patients will probably have certain rights according to the 
Cross-Border Healthcare Directive. The EU has also passed 
directives regulating medicinal products that also cover CAM 
medicinal products [4–6].
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1  The counsellor for health and food safety at the Mission of Norway to 
the EU. At the Mission of Norway to the EU we received updated in-
formation mainly on the European Free Trade Association (EFTA)/
EEA legal connection to EU legislation and the new Patients’ Rights 
in Cross-Border Healthcare Directive 2011/24/EU [3].
2  The European Commission Central Library. 
3  Meetings with the following NGOs provided important additional 
CAM documents and legal system information as well as viewpoints 
with regard to EU regulation:
   International Federation of Anthroposophic Medical Associations 
(IVAA) 
   International Council of Medical Acupuncture and Related Tech-
niques (ICMART) – EU Liaison Office
   The Association of the European Self-Medication Industry 
(AESGP).
We also collected information from European CAM associations/coali-
tions and other CAMbrella stakeholders.
This report covers 27 EU member states as well as 12 associated 
states. Each state is influenced by the EU legislation and has adjusted 
their national legislation depending on their connection to EU. The coun-
tries’ status in relation to the EU is shown in figure 1.
Results
Country-Specific Regulations
CAM treatment is in general either unregulated or regulated 
within the framework of the public health system. The only 
common factor that we have found across all 39 nations is the 
amazing ability they have demonstrated for structuring legis-
lation and regulation differently in every single country, no 
matter how small the size of the population.
Of the 39 countries, 17 have a general CAM legislation, 11 
of these 17 have a specific CAM law and 6 countries have sec-
tions on CAM included in their health laws (like ‘law on 
healthcare’ or ‘law on health professionals’). In addition to 
the general CAM legislation, some countries have regulations 
on specific CAM treatments (fig. 2).
The CAM regulations are either very general or very de-
tailed, and we found no more similarities between the coun-
tries that have a CAM law or general CAM legislation than 
between the countries with only specific CAM treatment reg-
ulations. Some of the general regulations are only a specifica-
tion of what CAM is, often to be supported by additional reg-
ulations or specifications issued by the Ministry of Health or 
the professions’ associations. In some countries additional 
specifications have not been made. As an example, both Nor-
way and Hungary have a CAM law. In Norway the CAM law 
is general without describing in detail the treatments or prac-
titioners, in Hungary CAM can be regarded as an integral as-
pect of the healthcare system. We found few similarities in the 
regulations of the specific CAM treatments between the 
countries, and it is challenging to find out who is allowed to 
practice the different treatments.
The 12 common treatment modalities vary considerably 
with regard to how many countries regulate the profession or 
practice in some way or another. Acupuncture is regulated in 
Previous studies on the European situation with regard to 
how CAM is regulated [7–9] have shown a diverse pattern. 
Reports from key CAM stakeholders have indicated that the 
regulatory situation has changed, and the CAMbrella consor-
tium has therefore seen it as important to establish the cur-
rent status in order to best prepare a roadmap for CAM re-
search in Europe.
The aims of this study were to:
1 Review in 27 EU member states and 12 associated states:
  The legal and regulatory status of CAM.
  The governmental supervision of CAM practices.
  The reimbursement status of CAM practices.
2  Review at the EU/European Economic Association (EEA) 
level:
   The status of EU/EEA-wide regulation of herbal and 
 homeopathic medicinal products.
3  Review and describe in all 27 EU member states and 12 
 associated states:
   The extent of country-specific market authorization of 
herbal and homeopathic medicinal products according to 
the EU directives.
4 Review at EU level:
  The status of EU-wide regulation of CAM practices.
   The potential obstacles for EU-wide regulation of CAM 
practices.
Methods
As an introduction we made a comprehensive overview of matters that 
may influence CAM in the European legislation. Descriptions of health 
issues, the legal and CAM terminology, and the interaction between con-
ventional medicine and CAM vary both in the EU bodies and within the 
39 countries included in this report. To address CAM-related legislation 
in the EU, we included both the EU legislation that influences the mem-
ber states’ national health legislation and various aspects of EU regula-
tion of conventional medicine.
Data underlying this report were collected from the 39 countries by 
communicating with the Ministries of Health, Law or Education, gov-
ernmental representatives, and members of national CAM associations. 
A search was also performed in the national websites/databases to 
identify official law documents. The scientific and non-scientific litera-
ture was also searched for documents and websites describing CAM 
regulation in each of the 39 countries. We also collected information 
from European CAM associations/coalitions, CAMbrella members, 
and stakeholders. Personal visits, including meetings with the ministries 
of health and CAM practitioners representing organizations, were 
made to 4 countries. Health authorities (if possible both legal and regu-
latory) were asked to verify the situation described for their specific 
country. 12 common treatment modalities have been described in detail 
in each country. In addition, a search was performed in the EUROPA 
and EUR-lex websites/databases to identify official EU law documents. 
We searched specifically for information about EU directives regarding 
European-wide healthcare-related regulation, as well as regulation of 
herbal and homeopathic medicinal products and their EU/EFTA/EEA 
implications.
A personal visit was also made to the EU offices and non-government 
organization (NGO) bodies in Brussels to establish firsthand updated 
 information. Meetings were held with:
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sence of regulation) was too unclear for us to be certain, we 
have inserted a question mark. Since the countries with CAM 
practitioners like ‘Heilpraktiker’, ‘healer’ and likewise may 
not be correctly represented, we decided not to introduce this 
table for other treatments because of the unclear situation.
Medicinal Products
Medicinal products are not defined as a part of health policy, 
and can therefore be regulated at the EU level. The individual 
states within the EU/EEA area are therefore no longer free 
to uphold a national regulation of medicinal products in viola-
tion of the following 3 EU directives.
1 Directive 2001/83/EC of the European Parliament and of 
the Council, of November 6, 2001 (on the community code 
relating to medicinal products for human use) [4].
2 Directive 2004/24/EC of the European Parliament and of 
the Council, of March 31, 2004 (amending, as regards tradi-
tional herbal medicinal products, directive 2001/83/EC on 
the community code relating to medicinal products for 
human use 2001/83/EC) [5].
3 Directive 2004/27/EC of the European Parliament and of 
the Council of March 31, 2004 amending directive 2001/83/
EC on the community code relating to medicinal products 
for human use (Text with EEA relevance) [6].
Until April 30, 2011, herbal medicinal products that were 
marketed without authorization before this legislation came 
into force could continue to be marketed under transitional 
measures defined in directive 2004/24/EC [5]. Now that this 
27 countries, anthroposophic medicine in 8 countries, Ay-
urveda in 5 countries, chiropractic in 27 countries, herbal 
medicine/phytotherapy in 11 countries, homeopathy in 25 
countries, massage in 20 countries, naprapathy (manual ther-
apy) in 2 countries, naturopathy in 9 countries, neural therapy 
in 3 countries, osteopathy in 16 countries, and finally Tradi-
tional Chinese Medicine in 10 countries.
As an example, figure 3 shows the regulation of home-
opathy across Europe. Switzerland has regulated home-
opathy and has registered homeopath as a profession in the 
EU  regulated professions database under ‘natural health 
practitioner’ as ‘naturopath/homeopath’. 2 countries (Latvia, 
Liechtenstein) have regulations that may be seen as a regu-
lation of a homeopathy profession. Latvia has regulated 
 ‘homeopathic doctors’, Liechtenstein has registered ‘natural 
health practitioner with a homeopathy specialty’. 22 coun-
tries have regulated homeopathy treatment. 14 countries 
have no specific homeopathic treatment regulations, but 
 general CAM or other health legislation may regulate 
 homeopathic practices.
Figure 4 ‘Homeopathy – Who may practise’ is an example 
of how difficult it can be to understand the consequences of 
national regulation. We have, to our best knowledge, listed 
whether the different categories of practitioners in each coun-
try are allowed to practice homeopathy. If only medical doc-
tors with additional CAM education are allowed to practice, 
we have put ‘No’ in the column for medical doctors. The same 
applies for other health personnel. If the regulation (or ab-
Fig. 1 The relationship of 39 countries to the 
EU.
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Marketing authorizations for herbal and homeopathic 
medicinal products are mainly given at the national level, 
but a central procedure can be used in some cases. Herbal 
and homeopathic medicinal products are subject to the 
time limit has expired, all herbal medicinal products that were 
previously unauthorized must have market authorization ac-
cording to directives 2001/83/EC, 2004/24/EC, and 2004/27/EC 
[4–6] before they can be marketed in the EU/EEA states.
Fig. 2. The status with regard to CAM general 
legislation in 39 European countries.
Fig. 3. Homeopathy regulation in 39 European 
countries.
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Fig. 4. An overview of groups that can legally practice homeopathy in 39 European countries.
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same application procedures as other medicinal products re-
garding manufacturing procedures, technical quality of the 
product, and all other requirements, with the possible ex-
ception of documentation of efficacy. There are 4 adminis-
trative procedures that can be followed to obtain a market 
authorization for these products (standard, well-established 
use, and 2 simplified registration procedures (one for home-
opathic medicinal products and the other for traditional-use 
registration of herbal medicinal products)). The simplified 
registration procedures allow alternative documentation of 
efficacy.
Homeopathic medicinal products covered by a registration 
or authorization granted in accordance with national legisla-
tion on or before December 31, 1993 and herbal medicinal 
products already authorized in accordance with regulation 
(EEC) No. 2309/93 [10] or supplied in response to a bona fide 
unsolicited order can be marketed irrespective of the 2 direc-
tives. These uniform regulations aim to supply citizens with a 
predictable standard of all medicinal products (including 
herbal and homeopathic) across Europe. Several stakeholders 
raised concerns before the rules were implemented. The con-
cerns focused mainly on leaving European citizens without ac-
cess to beneficial products and the establishment of unneces-
sary additional authorizational bureaucracy around safe 
products. 
EU-Wide Regulation
The directives, regulations and resolutions in the EU and the 
Council of Europe that may influence the professional prac-
tice of CAM, whether practiced by an authorized/licensed 
healthcare provider or by a provider without such authoriza-
tion/licensing, will also affect the conditions under which pa-
tients can receive CAM treatment(s) in Europe.
We have found no direct EU legislation of CAM except for 
directives concerning CAM medicinal products described 
above. 2 resolutions deal with non-conventional medicine:
 Resolution A4-0075/97: ‘Resolution on the status of non-
conventional medicine’. This is part of the European Par-
liament resolution on how non-conventional medicine 
should be included more formally as a special field in the 
European legislation [1]. 
 Resolution 1206 (1999): ‘A European approach to non-
conventional medicines’ of the Parliamentary Assembly 
of the Council of Europe resolution on non-conventional 
medicine [2].
How legislation connected to ‘The 4 Freedoms’ is handled in 
EU/EEA, influences the national CAM legislation and legis-
lation that impacts directly or indirectly on CAM of the indi-
vidual states. Of particular interest is how patients and health 
professionals are able to relate to diverse national CAM regu-
lations. European CAM practitioners have different levels of 
training as a basis for their practice, whether they are formally 
licensed or not, and patients have varying expectations de-
pending on experiences from their home country.
Harmonization of training and regulation of non-conven-
tional disciplines is only marginally covered in the directive 
2005/36/EC Professional Qualifications [11]. In many states 
only doctors or other health professionals are allowed to prac-
tice CAM according to national health regulation. The EU-
regulated professionals database includes only a few CAM 
professions in some member states. We have found that the 
resolutions on the status of non-conventional medicine from 
1997 and 1999 have not been followed up with harmonized 
CAM training or regulation.
Discussion
Our findings demonstrate an extraordinary diversity with re-
gard to the regulation of CAM practice across Europe. At the 
same time the medicinal products that CAM practitioners will 
be prescribing or recommending are regulated uniformly 
across the same geographical area. This regulatory diversity 
will profoundly influence patients, practitioners and research-
ers when crossing European borders. 
When patients cross borders in search of CAM treatment, 
they may encounter substantial differences in the professional 
background of apparently identical CAM providers who are 
mostly also working under completely different reimburse-
ment systems. In post-modern Europe, where patient choice 
in healthcare is seen as a core value [12], this confusing Euro-
pean market makes any informed treatment-seeking challeng-
ing. This heterogeneous situation influences CAM patients’ 
rights, access and potential safety, and constitutes a challenge 
to a harmonized national and European follow-up of the 
new Patients’ Rights in Cross-Border Healthcare Directive 
2011/24/EU [3].
When practitioners cross borders they will encounter a sub-
stantial variety of CAM practice in Europe. This raises seri-
ous concerns with regard to the predictability, quality and 
safety of healthcare delivery to European citizens. When 
CAM professions in some countries are tightly regulated, 
while the same professional categories in other countries are 
totally unregulated, establishing a common collegial ground is 
very challenging.
When researchers cross borders they will find that research 
on efficacy and effectiveness of CAM is severely hampered by 
the conglomerate of European regulation. Practices and prac-
titioners are not comparable across national boundaries, and 
any observational or experimental study will therefore be 
generalizable only within a narrow national or cultural 
context. 
The European Parliament resolution on non-conventional 
medicine from 1997 [1] stated that non-conventional medical 
disciplines should be clearly identified and defined. We have 
found few overall clear distinctions between conventional and 
non-conventional medicine in the EU legislation. An adequate 
regulation and supervision of CAM professionals and CAM 
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therapies will require special knowledge in the CAM field to 
take into account the special features of this field of health-
care. Developing the European legislation of CAM by simply 
adapting the criteria of conventional medicine will probably be 
inadequate for regulation of the CAM field. Similar to the way 
that CAM research needs some particular considerations com-
pared to research on, e.g., conventional pharmaceuticals [13], 
the methods by which CAM is regulated must be specifically 
tailored to its inherent qualities.
In particular, the Patients’ Rights in Cross-Border Health-
care Directive [3] respects the established differences in na-
tional healthcare systems. It aims to remove obstacles to the 
fundamental freedoms that enable patients from one EU 
member state to choose to seek treatment in another EU 
member state. The directive also outlines the responsibilities 
of EU member state healthcare systems to cover treatments 
given in other member states. Regional collaboration be-
tween providers, purchasers, and regulators from the differ-
ent member states can ensure safe, high-quality, and efficient 
cross-Border healthcare at a regional level. Historical and 
cultural similarities between neighbouring countries would 
thus seem to potentially facilitate cross-border opportunities 
in the CAM area more than EU-wide directives, regulations 
and decisions.
The most important obstacles that hinder the European 
Parliament resolution call for ‘a process of recognizing non-
conventional medicine are the Treaties of Rome and Lisbon 
[14], which clearly state that the individual member states 
have the responsibility for ‘the definition of their health policy 
and for the organization and delivery of health services and 
medical care. The responsibilities of the member states shall 
include the management of health services and medical care 
and the allocation of the resources assigned to them. This le-
gitimizes and sustains the wide variations in CAM regulation 
across Europe.
Another obstacle is the unwillingness of the individual Eu-
ropean countries to voluntarily harmonize their legislation 
and regulation of CAM with other European states. If this 
had been done to a greater degree, both patients and provid-
ers would be able to benefit from The Right to Move and 
 Reside Freely Directive [15], the Professional Qualifications 
Directive [11], the Patients’ Rights in Cross-Border Health-
care Directive [3], the Services Directive [16], and the Social 
Security Regulation [17].
There are in principle, therefore, 2 options that can be cho-
sen to achieve a higher degree of harmonization: legislation 
and regulation at the EU/EEA level or voluntary harmoniza-
tion. We do not foresee EU/EEA level legislation/regulation 
in the foreseeable future since the EU has repeatedly upheld 
its position of leaving this to the individual country. Voluntary 
harmonization is, however, possible within current legislation. 
We think it is important to encourage individual states within 
culturally similar regions to harmonize their CAM legislation 
and regulation. This broader regional perspective can proba-
bly safeguard against inadequately justified over- or under-
regulation at the local level. The successful mutual recogni-
tion of physiotherapists across Europe shows how this can be 
done. Physiotherapy has a long tradition of being a recog-
nized profession with well-established international research 
on the importance and effect of physiotherapy treatment. The 
European collaboration within the World Confederation for 
Physical Therapy Europe (WCPT-E) and the European Net-
work of Physiotherapy in Higher Education (ENPHE) leads 
to exchange of experience and harmonized regulation, educa-
tion and professional issues within the EU and the European 
countries. This could be a potential template for development 
of harmonized regulation of CAM professions in Europe [18].
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Regulation and Professionalization in Complementary and Alternative 
Medicine: historical perspectives and contemporary concerns 
An international and interdisciplinary conference 
 
The provision and use of traditional, complementary and alternative medicines (usually referred 
to as CAM) has been growing in the UK and other industrialized nations over the last 40 years. 
CAMs include traditional healing practices, such as acupuncture and Ayurveda, complementary 
treatments such as aromatherapy or massage, and alternative medical systems, such as 
osteopathy or homeopathy. 
To date, most of the academic research in CAM has focused on issues of efficacy and 
effectiveness, rather than on historical, social and legal aspects of practice. This 
interdisciplinary conference will focus on two central concepts: regulation, the legal 
frameworks for practitioners (products will not be covered) and professionalization, the socio-
political process of becoming a recognised profession.  Both concepts will be considered within 
their historical context and in terms of their conceptual purchase in terms of contemporary 
concerns and debates.   
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Dr Nicola Gale (n.gale@bham.ac.uk)  
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for Health Law, Science and Policy, The History of Medicine Unit, The Centre for 
Biomedical Ethics and The Complementary and Alternative Medicine Birmingham 
Research Alliance (CAMBRA) at The University of Birmingham.   
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Conference Programme 
 
 
9.00am  Registration (tea and coffee) 
 
9.30am  Welcome (Jean McHale and Nicola Gale) 
 
9.45am  KEYNOTE  
Mike Saks, Professor of Health and Community Studies and Provost at 
University Campus Suffolk, UK 
 Power and professionalization in CAM: historical and contemporary 
perspectives 
 
10.30am Break (tea and coffee) 
 
10.45am  WORKSHOP: professionalization (Chair: Nicola Gale) 
(see below for details of workshop format) 
 
• Sandy Welsh, Heather Boon, Merrijoy J Kelner, Beverly Wellman (Canada) – 
Traditional Chinese Medicine and Acupuncture Practitioners and the Canadian Health 
Care System:  The Role of the State in Creating the Necessary Vacancies. 
• Jane Wilkinson, Nicola Gale (UK) – Towards a learning profession: A critical evaluation 
of the relevance of clinical governance for complementary and alternative healthcare 
services 
• Jane Adams (UK) – Developing Naturopathy in Britain 1920-1950 
• Sarah Cant (UK) – ‘The Knowledgeable Doer’: Nurse and midwife integration of 
complementary and alternative medicine in NHS hospitals. 
 
12.20 pm Group photograph 
 
12.30 pm Lunch and Postgraduate Poster Presentations 
 
• Joana Almeida (UK) - Recent CAM Manoeuvring within the Mainstream Health-Care 
System in Portugal 
• Romila Santosh (UK) - The current practice of Ayurveda in the UK. Practitioner and 
patient perspectives. 
 
        
         
1.15 pm KEYNOTE  
Julie Stone, Visiting Professor in Ethics, Peninsula Medical School, UK 
 Aspiration, Integration, Regulation: CAM’s uneasy relationship with the State 
 
2.00 pm WORKSHOP: regulation (Chair: Jean McHale) 
(see below for details of workshop format) 
 
• Marie-Andrée Jacob (UK)  – ‘A responsible body of scientific opinion’: Research 
integrity and conduct, and the regulation of CAM 
• Ayo Wahlberg (Denmark) – What is a ‘dangerous’ practitioner? Technologies of 
assurance in CAM practice today 
• Ruth Barcan (Australia) – Intuitive Medicine: Ethics, Regulation and 
Incommensurability 
• Solveig Wiesener, Vinjar Fønnebø (Norway) – CAM in Europe – a complex legal and 
regulative situation.  Will harmonized EU-wide regulation strengthen CAM research 
and practice?  
 
3.45 pm  Break (tea and coffee) 
 
4.15 pm Panel Discussion and Moving Forward 
Panel Members:  Prof Julie Stone, Prof Marie Fox, Prof Heather Draper, Dr Jonathan Reinarz 
The purpose of the conference is to look at the past, present and future of CAM regulation and 
professionalization, and to develop a framework for future research in the field.   This final 
session will draw together key themes that have emerged, discuss publications and a potential 
future research programme. 
 Is enhanced professionalization/ regulation inevitable and/or desirable? 
 Is CAM really any different than any other area of medicine in relation to the 
professionalization/ regulation issues that it raises and, if so, in what ways? 
 Are professionalization and regulation inextricably linked? 
 What is the impact of the discourse of patients’ rights upon professionalization and 
regulation in CAM? 
 Will the EU provide a fundamental driver to change in this area in the future? 
 Are we learning from history or are we ‘reinventing the wheel’? 
 What is going to drive the debate forward in the next few years? 
 
5.00pm  Close 
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 CAM in Europe – a complex legal and regulative situation. Will harmonized EU-wide 
regulation strengthen CAM research and practice?  
Wiesener S., Fønnebø V.  
Conventional medicine in Western countries is generally organized similarly across countries, continents and 
cultures. Each country regulates the practice of medicine along mutually recognizable patterns. The 
professional categories are similar, and within EU/EEA (the European Economic Area) an established 
system of mutual recognition of the other countries’ licensing or authorization is in place. This system is in 
place despite the Lisbon Treaty declaration of the right of each country to organize the health care system 
separately from each other. EU has deliberately decided not to introduce an EU-wide regulation of health 
care. The substantial similarity of the national health care systems, however, enables strong international 
collaborations within both research and practice.  
Complementary and Alternative Medicine (CAM) is a diverse system of “health care” which has only one 
common feature across Europe: It is alternative or complementary to conventional health care. Although 
this system of care is present throughout Europe and beyond, it does not necessarily have the same name, 
structure or function within each country. There is no implicit commonality shared by either the national 
authorities or the practitioner communities.  
The Pan-European research network CAMbrella was established in 2010 funded by the 7th Framework 
Programme in EU. The objective of this coordination project is to assess CAM across Europe, and come up 
with a roadmap for future research to ensure the peoples of Europe safe and effective practices also in this 
area of “health care”. One of the main aims of this project is to review the legal and regulatory status of CAM, 
and indicate how legal and regulatory differences can be taken into account both in research initiatives and 
efforts to secure equal access to health services across Europe.  
Material and Methods  
Thirty-nine countries covering EU, EFTA, EU candidate -and associated countries are included in this 
overview. In order to describe the legal and regulatory status we have collected legal and regulation 
documents from each country and EU. Additional information has also been acquired by questionnaires 
and personal visits.  
CAM practitioners are heterogeneously classified and the CAM terminology differs within Europe. A full 
description of CAM terminology is forthcoming under the responsibility of a different group within 
CAMbrella.  
To identify how CAM providers and treatments are legislated and regulated it was necessary to study both 
general health care legislation/regulation and, if established, CAM legislation/regulation. This is due to the 
fact that CAM can either be legislated/regulated in general health care legislation/regulation as something 
that is or is not included there, or it can be separately legislated/regulated. It was also necessary to relate to 
differences in education, curriculums, and licensing/authorization/registry systems.  
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The work in the CAMbrella project is still under way, and we can therefore at this moment in time only 
report on EU-wide systems that potentially affect the legislation/regulation of CAM within countries and 
some aspects of legislation/regulation within individual countries.  
Results  
Europe -policies and legislation  
Health policies are a national responsibility for the EU Member States. This is confirmed in the Lisbon 
Treaty in TITLE XIV Public Article 168 number 7:  
“Union action shall respect the responsibilities of the Member States for the definition of their health policy 
and for the organisation and delivery of health services and medical care. The responsibilities of the 
Member States shall include the management of health services and  
medical care and the allocation of the resources assigned to them.”  
The Parliamentary Assembly of the Council of Europe passed a Resolution already in 1999 supporting the 
EU view, but at the same time calling for a common European approach to what they classify as “non-
conventional medicine”: “In the health field, it is important to preserve the diversity of national legislation and 
practise that is one of Europe’s assets: people’s attachment to their own systems and tradition must not be 
called into question. Nevertheless, the Assembly believes that a common European approach to non-
conventional medicine based on the principle of patients’ freedom of choice in health care should not be 
ruled out.”…..“The Assembly believes that the best guarantee for patients lies in a properly trained 
profession, which is aware of its limitations, has a system of ethics and self-regulation and is also subject to 
outside control.” [1]  
EU has established several legal documents that influence national health and CAM related legislation in the 
EU and EU-associated countries. The new Cross-border Health Directive (The Patient Rights Directive) 
passed in February 2011[2] is one example of how EU legislation will influence national health 
reimbursement systems, health priorities and patient safety aspects. According to this Directive a person 
living in the EEA-area can choose health treatment in all the EEA Member States. Expenses will be 
reimbursed according to the home country regulations while treatment/provider regulations will follow the 
legislation in the country where the treatment has been given. Since the reimbursement and regulation of 
CAM practices differ substantially between countries, the consequences of this Directive could be that 
patients’ rights with regard to equal access to health treatment in Europe could be challenged.  
“The Four Freedoms” stated in the EU Treaties aim to enable goods, services, capital and persons to move 
freely within EEA. Education, training, employment, enterprise and civil protection are fields included in the 
regulations. National regulations of CAM practitioners, treatments, supervision and reimbursement do not 
follow an EU-wide harmonized system and are not covered by mutual recognition systems. Consequently the 
differences in CAM regulation challenge the free movement of patients and practitioners in Europe.  
 
As mentioned in the introduction EU has required all countries to mutually recognize certain professional 
categories, some of these categories include doctors, nurses and other health care personnel. This mutual 
recognition requires established systems of licensing/authorization in each country. A similar mutual 
recognition for CAM practitioners has not been established.  
Individual countries -policies and legislation  
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Even though some countries studied have passed specific CAM legislation/regulation over the past few 
years, there are few, if any, signs of harmonization in Europe. Regional legislation/regulation similarities 
seem more based on common historical development within health treatment cultures than a conscious effort 
to facilitate cross-border cooperation and ease of access for patients.  
 
We have, however, identified two main approaches to regulation; countries where all practice of CAM is 
regulated in some way or another (Examples: Germany, Hungary, Belgium) and countries that do not 
regulate the field at all or only regulate some of the CAM treatments (Examples: Latvia, Norway, 
Sweden)[3].  
Countries regulating CAM often do it within the framework of health care regulation in general. Some 
countries limit the licence to practice CAM to medical doctors (Example: France), while other countries 
have started to licence also other practitioner categories (Example: Hungary).  
Reimbursement of CAM treatment also varies considerably within Europe. Most countries reimburse no 
expenses associated with CAM treatments, but there are examples of exceptions to this: Some health 
insurance companies in Germany reimburse selected treatments, Switzerland has decided (after a 
referendum) to reimburse five main modalities from 2012 and Norway covers CAM treatments given in 
hospitals.  
Risk and safety aspects  
The differences in legislation make it challenging to ensure safe practice of CAM across boundaries in the 
EU/EEA area. All countries have established national health supervision systems for health professionals 
(doctors, nurses, midwifes a.o.). This system will only apply to CAM practitioners in countries where the 
same practitioners are regulated as health personnel. In countries where “only doctors are allowed to treat 
….” sick individuals one should think that patient safety is ensured. But even there the safety of patients 
with regard to CAM treatments could be at risk. With the EU mutual recognition of medical doctors, some 
physicians could be well qualified for CAM treatments, while others, immigrating from countries with no 
education/training in CAM in the medical curriculum, will be totally unqualified to practice CAM. Safety 
aspects will accordingly be based on a potential of unlike skills and knowledge level for CAM practitioners in 
Europe.  
The established monitoring systems with regard to adverse reactions is mainly tailored to 
pharmaceutical drugs, and CAM supplements are therefore monitored for safety in a very 
rudimentary way.  
 
Discussion and issues for workshop dialogue:  
Our study so far shows that diversity is still the best word to describe the legislation/regulation of CAM in 
Europe. This impacts pan-European professional collaboration and development, patient access and safety 
as well as international clinical research collaboration.  
The most important issue is how European patients can be secured safe and best quality health treatment 
when they choose CAM. With patients more willing to cross borders in their search for health care 
(encouraged by the recent Cross-border Health Directive), it is imperative that they are aware of the different 
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status of CAM in culturally similar European nations. In the current situation the most important issue that 
can assist patients is an easily accessible source of information. When they cross European borders for CAM 
treatment, they need to be aware of the potential substantial differences in professional background of 
apparently identical professional CAM providers in the European countries. They also need to be aware of 
varying reimbursement systems and how they are safeguarded if the treatment results in unwanted adverse 
or side effects.  
Health authorities throughout Europe need to discuss how the safety of their patients can be 
safeguarded under the current regulatory system in Europe. The supervision systems used for 
conventional medicine may be ineffective and even inappropriate when monitoring the CAM field. 
Before passing further regulations of CAM practices, both national authorities and EU should generate 
specific knowledge on how the current regulations influence patients’ safety when using CAM 
treatments.  
Another issue is professional collaboration and development. When CAM professions in some countries 
are tightly regulated while the same professional categories in other countries are totally unregulated, 
common ground is difficult to be established between “colleagues”. A licensed acupuncturist in Hungary will 
have considerable challenges in relating to a “colleague” in Norway practicing the profession on the basis of 
three weekend courses 10 years ago. How is it feasible to facilitate cross-border professional development 
under the current regulatory system in Europe, and what would the advantages and disadvantages be for 
practitioners if CAM were regulated at an EU/EEA level? These questions should be discussed within 
professional organizations in CAM before any further EU legislation is considered. Since the regulation of 
CAM professionals in many countries closely resembles the regulation of conventional health professionals 
the issue must be discussed with a comprehensive focus.  
A third important issue is clinical research collaboration. Research on efficacy and effectiveness of CAM 
is severely hampered by this conglomerate of European regulation. Practices and practitioners are not 
comparable across national boundaries, and any observational or experimental study will therefore be 
generalizable only within a narrow national or cultural context. Research should be strengthened on the 
monitoring and safety aspects on CAM practices. An essential discussion to be initiated is how to develop 
the current regulatory system in Europe to improve and facilitate cross-border clinical CAM research, and 
what would the advantages and disadvantages be for researchers if CAM were regulated at an EU/EEA 
level?  
The legislation/regulation currently in place at a national level for conventional medicine has been largely 
used as a blueprint for CAM legislation/regulation. Whether this is an appropriate choice should be 
evaluated thoroughly. One important issue is whether Europe should follow the Far East where parallel 
legislation/regulation systems are established for conventional medicine and “traditional medicine”, or 
whether it would be best to incorporate all health-related treatment practices in one single system of 
legislation/regulation.  
Finally, legislation and regulation is seen as an important instrument to ensure a safe practice of treatment. 
The attractiveness of CAM can for many patients be seen as seeking something outside of the 
“establishment”. This is in line with the postmodern partial distrust of the rationality of the past. If currently 
used CAM treatments are regulated into the “establishment”, patients might still be inclined to seek the 
alternative, having options that might be even more ineffective and risky. “Over-regulating” CAM practices 
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could consequently possibly endanger patient safety.  
There is still a considerable knowledge gap in factors of high importance when making political choices about 
CAM legislation and regulation across Europe. Of special and urgent importance is to clarify advantages and 
disadvantages for patients/practitioners/researchers of regulating CAM at an EU/EEA level.  
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Attachment 3: Template example – the description of Romania 
1.1 Romania 
Romania has been a member of the European Union since 1 January 2007(1). Romania 
became a member of the Council of Europe in 1993(2). 
1.1.1 The legal and regulatory status of CAM and CAM practices 
In 2005 and 2007 national CAM legislation was introduced and from 2007 adjusted to EU 
Directives and Regulations. The new classification of occupation issued by order of the 
government 1832/2011 includes for the first time the denomination “non-MD associate 
practitioners of CAM”(3). 
From 2007 citizens' rights and access to CAM therapies are regulated by “Law on 
Complementary and Alternative Medicine nr. 118/2007” (4). The law regulates the activities 
and practices of Complementary and Alternative Medicine for the prevention of illnesses 
and the promotion of health, healing of diseases and optimization of the human health from 
the biopsychosocial and spiritual points of view(4, 5). 
According to chapter III, Art.16 in the Law on CAM nr 118/2007(4) all persons have free 
access to the treatments and practices of complementary and alternative medicine, 
regulated according to the law. Law nr.118/2007 states that patients receiving CAM 
treatment must receive information, preferably written, accessible and easy to understand 
of the benefits and risks of CAM treatment(3). CAM therapies legally practised in Romania 
are grouped in pharmacologic and biological therapies, herbal practice, diet-nutrition and 
lifestyle, alternative therapies, manual therapies, energetic and bio-electromagnetic 
applications. The therapy group “alternative therapies” includes among others 
acupuncture, homeopathy, naturopathy, ayurveda and Chinese medicine(3). Among others 
the group “manual therapies” includes chiropractic, osteopathy and massage. 
In 2005 the Ordin nr. 418/2005 National Catalogue of Programmes for CAM studies was 
established. The studies were organized, according to Art I, in order to certify the 
competence of medical doctors, dentists and pharmacists and the methodological standards 
for its organisation and progress(5, 6). CAM studies included were among others 
acupuncture, homeopathy phytotherapy and apitherapy. 
According to the Ordin nr. 418/2005 “Certification of graduation in the programme of 
complementary studies implied obtaining a competence issued exclusively by the Ministry of 
Health through the National Center of Continuous Education Bucharest only for medical 
doctors, dentists and pharmacists”(6). 
Only medical doctors (MDs), dentists and pharmacists are allowed to practise acupuncture, 
homeopathy, apitherapy, phytotherapy, chiropractic, osteopathy and TCM. CAM practices 
are regulated by the Ministry of Health (7) and the CAM professions are recognized as an 
additional qualification for medical doctors(8). “In order to become a practitioner of 
complementary/alternative medicine, the persons (medical doctors, dentists, pharmacists, 
psychologists) are obliged to add the specific competence obtained (acupuncture, 
phytotherapy, homeopathy..), with the approval of the National Center of Continuous 
Education for Medical Doctors, Dentists and Pharmacists Bucharest(4) on the authorization 
of free practise provided, according to the law, by the Ministry of Public Health”. CME is not 
obligatory for approved CAM therapy doctors(8). 
According to the CAM Medical Practitioners Order specialized committees for certain areas 
of practice (e.g. acupuncture, herbal therapy, homeopathy, apitherapy) will regulate 
professionals(6). 
“In medical schools or faculties of pharmacy, students can take optional courses in 
homeopathy, phytotherapy or acupuncture, but none of the CAM modalities are taught in 
the core curriculum. Attempts are being made to arrange postgraduate courses in 
integrative medicine, accredited by the Romanian College of Physicians and addressed 
mainly to general practitioners”(7). 
Romanian national CAM law on patients’ rights complement the formulations given in the 
2011/24/EU Directive on the application of patients' rights in cross-border healthcare(7, 9). 
“Practitioners without a diploma of MD, dentist or pharmacist are authorized to practise 
CAM therapies (except those allowed only to MDs) after a short special training accredited 
by the Ministry of Health”(7). 
We found no CAM professions registered for Romania in the EU regulated professions 
database (Directive 2005/36/EC)(10). 
1.1.2 The governmental supervision of CAM Practices 
Supervision and practice control activities of CAM in Romania is regulated by the law on 
professional organizations of medical practitioners of CAM (3). 
• With the Medical Practitioners Order, CAM specialized committees for each area of 
practise of CAM, are bound to regulate professional practitioners in the specific area. 
• The Order of Practitioners of CAM is required to develop code of ethics, supported by 
specialist committees. Code of ethics includes the rights to practise, disciplinary 
sanctions for professional incompetence, practise restrictions in case of 
incompatibility or damage to patient health. 
• A register of practitioners of CAM is held at the headquarters of the Order of 
Practitioners of CAM, communicating with the National Centre for Training in 
Healthcare. 
• The Ministry of Public Health, College of Physicians in Romania, Dental College and 
College of Pharmacists in Romania shall, in consultation with the Order of 
Practitioners of CAM, approve studys curricula for institutions that prepare 
practitioners of CAM to ensure level qualification. 
• The Ministry of Public Health and the National Training Center in Healthcare, 
Department of CAM directs and controls activities in the field, including professional 
training for practitioners of CAM. Department of CAM supplies and accredits training 
programs for practitioners of CAM(3). 
1.1.3 The reimbursement status of CAM practices and medicinal products 
CAM treatment and medicinal costs are partially covered for acupuncture, homeopathy, 
phytotherapy and psychotherapy (House of National insurance of Health)(8, 11). Since 2010 
manual therapies are not covered anymore due to the economic crisis in Romania(3). 
1.1.4 Acupuncture 
Acupuncture is legally recognized as a CAM therapy in the group “alternative therapies” in 
the law on CAM 118/2007(4). 
Only medical doctors, dentists and pharmacists with approved additional qualification are 
allowed to practise acupuncture in Romania(6). A specialized committee for acupuncture 
regulates the profession (NATL)(6). 
In medical schools or faculties of pharmacy students can take optional courses in 
acupuncture(7). 
There is a professional society of acupuncture that has annual national congresses. There is a 
National Institute of research in CAM in Bucharest; its present director is also the president 
of the Romanian association of Acupuncturists(3). 
There is no professorial chair for CAM therapy in Romania, but there are clinics of 
acupuncture in some faculties of medicine and hospitals of education and research(8). 
1.1.5 Anthroposophic medicine 
In Romania diplomas for anthroposophic doctors are not recognized. Postgraduate training 
courses in anthroposophic medicine are provided at private teaching centers(11). “The 
national associations of anthroposophic doctors require their members to complete 
significant numbers of hours of CME in anthroposophic medicine”(11). 
1.1.6 Ayurveda 
Ayurveda is legally recognized as a CAM therapy in the group “alternative therapies” in the 
law on CAM 118/2007(4). 
There is a course that provides accredited qualifications in Ayurveda organized by the NATL 
Center for Training in Health care. Only MD’s, dentists, nutritionists can participate(3). 
1.1.7 Chiropractic 
Chiropractic is legally recognized as a CAM therapy in the group “manual therapies” in the 
law on CAM 118/2007(4). 
Only medical doctors, dentists and pharmacists with approved additional qualifications are 
allowed to practise chiropractic in Romania(6). The therapists allowed to practise specialized 
kinetic therapies are called kinetotherapists in Romania (see other treatments)(3). 
1.1.8 Herbal medicine/Phytotherapy 
Herbal therapy is legally recognized as a CAM therapy in the group “herbal practice” in the 
law on CAM 118/2007(4). 
Only medical doctors, dentists and pharmacists with approved additional qualification, 
minimum a one year course with a diploma of competences, are allowed to practise 
phytotherapy in Romania (6). A specialized committee for herbal therapy regulates the 
profession(6) and there is an association of MD phytotherapists. ANATECOR (national 
association for CAM therapies) organizes courses of herbal therapies for practitioners, and 
the courses are approved by the Ministry of Labour(3). 
In medical schools or faculties of pharmacy students can take optional courses in 
phytotherapy(7). 
1.1.9 Homeopathy 
Homeopathy is legally recognized as a CAM therapy in the group “alternative therapies” in 
the law on CAM 118/2007(4). 
Homeopathy has historically from 1981 and 1995 been recognized by law as a distinct 
therapeutic system in Romania. Practise has been limited to medical doctors with specific 
homeopathic training(11). 
Only medical doctors, dentists and pharmacists with approved additional qualification are 
allowed to practise homeopathy in Romania(6). A specialized committee for homeopathy 
regulates the profession(6) and. both by law and by the medical association, homeopathy is 
recognized as a medical specialty(6, 11). Diplomas of homeopathic doctors are approved by 
the government according to law and regulations(6, 11). 
In medical schools or faculties of pharmacy students can take optional courses in 
homeopathy(7). Postgraduate training courses in homeopathy for doctors are provided at 
universities and homeopathy is an official part of the Continuous Education Programme for 
doctors (6, 11). Homeopathic doctors’ associations require a number of obligatory CME for 
their members(11). 
1.1.10 Massage 
Massage is legally recognized as a CAM therapy in the group “manual therapies” in the law 
on CAM 118/2007(4). 
Massage courses are offered by training providers authorised by CNFPA – Consiliul National 
de Formare Profesionala a Adultilor. Participants to the courses are awarded with a 
Certificate, recognized by the Ministry of Labour, Family and Social Protection and Ministry 
of Education, Youth and Sports. The Certificate will be accompanied by a transcript 
explaining the professional competencies acquired(3). 
Certificates awarded for the courses enjoy professional recognition, according to law (OUG 
129/2000 Republished) and can be registered in the Employment Record for the relevant 
professional occupation, based on the Classification of Occupations in Romania (COR)(12). 
Further qualifications can be obtained, as detailed on the website of the Association of 
Professional Masseurs, www.maseuri.ro/useful/certified.php(3). 
1.1.11 Naprapathy 
We have not found legislation on naprapathy in Romania. 
1.1.12 Naturopathy 
Naturopathy is legally recognized as a CAM therapy in the group “alternative therapies” in 
the law on CAM 118/2007(4). 
1.1.13 Neural therapy 
We have not found legislation on neural therapy in Romania. 
1.1.14 Osteopathy 
Osteopathy is legally recognized as a CAM therapy in the group “manual therapies” in the 
law on CAM 118/2007(4). 
Only medical doctors, dentists and pharmacists with approved additional qualification are 
allowed to practise osteopathy in Romania(6). 
1.1.15 Traditional Chinese Medicine (TCM) 
Chinese medicine is legally recognized as a CAM therapy in the group “alternative therapies” 
in the law on CAM 118/2007(4). 
Only medical doctors, dentists and pharmacists with approved additional qualification are 
allowed to practise TCM in Romania(6). 
1.1.16 Other treatments (mentioned if found in legislation) 
Physiotherapy/Kinetotherapy (physiotherapy/chiropractic) is a regulated profession in 
Romania with the title “Kinetoteraput”.  The title and the professional activity are protected 
by the state. The rules of professional conduct are determined directly by the state through 
national legislation. The physiotherapist must be state registered and obtain a licence to 
practise(13). Kinetotherapists have a higher education, usually 3 or 4 years. The law 
regulating kinetotherapy was issued in December 2009. The profession is regulated by the 
National Order of Kinetotherapists. http://kinetoprofesional.blogspot.com/2009/03/proiect-
lege-al-ordinului.html(3). Romania has established a code of ethics for physiotherapists. The 
national authority responsible for the physiotherapy profession in Romania is the Romanian 
Federation for Physical Therapy (FRAK)(13). 
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Attachment 15.4. Template for country emails and telephone calls. 
Dear XXX 
I have received your address from XXXXX, and I really hope for your help. Alternative 
additions: (As I understand you are the one that have filled the questionnaire about CAM in 
your country, which I have received from XXX). (I am sorry I do not know anything more 
about you, however that can be filled out later). 
We are planning an information travel from Tromsø, Norway to XXX from “date, time”. 
Hopefully we are able to have meetings with people that know well the legislation of 
Complementary and Alternative, traditional medicine in your country. As I understand you 
have contacts in the MOH and can arrange meetings with representatives. 
So for the background story: 
I am reviewing how CAM (Complementary and alternative medicine) is regulated and 
included in legislation in Europe. We have insufficient information from some of the 
European countries, included XXX (country). 
NAFKAM at the University of Tromsø, Norway is a partner in the EU research programme 
CAMbrella where we are heading the Work Package 2 – legal questions. 
http://www.cambrella.eu/home.php home site 
http://www.cambrella.eu/home.php?il=69&l=deu legal WP 
XXX  (is a member of our Work Package group about legislation for CAM in European 
countries, or member of XXX CAM association) and has given me your address. 
I would really appreciate making contact with expertise in this question in your country. It 
would be of great help if you could please forward this inquiry to the right persons and help 
me to arrange for meetings.  
It could be of interest to make an appointment in The Ministry of Health in XXX (country). 
Contacts who know about CAM legislation/regulation is of great interest. 
Our focus is: 
• - 1     The legal status of CAM 
• - 2     The regulatory status of CAM practices 
• - 3     The governmental supervision of CAM practices 
• - 4     The reimbursement status of CAM practices and medicinal products 
• - 5     The regulation of CAM medicinal products 
Secondary I am very interested in documents describing the issues. The documents have to 
be translated into English- or a summary in English with the original language as attachment 
with reference information. 
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I really hope you can help me 
Yours sincerely 
Solveig Wiesener 
Senior Adviser 
NAFKAM : National Research Center for Complementary and Alternative Medicine University 
of Tromsø, Tromsø, Norway 
http://www2.uit.no/ikbViewer/page/ansatte/organisasjon/hjem?p_dimension_id 
=88112&p_menu=42374&p_lang=1 
Mobile: +47 90518648 
Email: solveig.wiesener@uit.no 
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Attachment 15.5 Template: Interview and description for each country and 
treatment 
The legal and regulatory status of CAM and CAM practices 
• Legal connection to EUEFTA/EEA and Council of Europe 
• CAM general legislation 
• Specific treatment (one excel sheet for each treatment) regulation 
• EU title (Directive 2005/36/EC) 
• Regulated profession/ protected title 
• Statutory register 
• Medical Doctors (MDs) may practise 
• Medical Doctors with CAM training may practise 
• Conventional practitioners (CPs) (PS3 post-secondary level 3-4 years) may practise 
• Conventional health personnel with CAM training may practise 
• CAM practitioner (CAM trained personnel, medical trained, DSE diploma post- 
secondary education level) may practise  
• Others may practise 
• Other CAM legislation 
• Notes 
Check list for questions, definitions, terminology and clarifications: 
CAM Legislation 
The legal status of CAM treatments and practices are mostly regulated through  
• Laws and governmental regulations on  health care (conventional and CAM)  
• General CAM legislation by law or governmental regulation 
• Regulation of specific CAM practices and treatments 
• No CAM specific legislation or regulation 
 
CAM practices and treatment could also be regulated through other laws and regulations like 
criminal code, education, social security, finance and reimbursement regulations.  
One issue is if the practitioner has a protected title either through EU Directive 2005/36/EC(1) 
on recognition of professional qualifications or as a national protected title in the specific 
country. 
 
The level of education and training could be statutory regulated or voluntary. Some of the 
European Associations for doctors or CAM practitioners have developed guidelines to be 
followed for their members. We will also find regulations of governmental registries which 
could be statutory, voluntary and/or included in the membership of the different associations. 
 
The national CAM/health legislation and regulation consists mostly of guidelines for 
permission or restriction to treat patients with the specific CAM treatment. This consists of 
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educational and/or training requirements and systems for authorizations and licenses. 
Requirements for registers and self-regulation are often included in the regulation of the 
practices. Self-regulation is mostly divided into statutory or voluntary requirements. 
 
CAM Practices 
Regulation of practices is mostly connected to formal education and/or training in 
conventional or non-conventional medicine. This is mostly divided into the following way: 
A. Medical Doctors (MDs) 
We have found different classifications: Medical doctor, medical doctor with CAM 
education, medical doctor with CAM licence, medical doctor with CAM authorization, 
physician, CAM physician, Allopathic doctor, non-allopathic doctor. In our report we 
will divide into Medical doctor (MD) and CAM MD (medical doctors with CAM 
training may practice). 
B. Health professionals 
In most cases this is conventional health personnel with an educational level of 3-5 
years. Nurses and midwifes are the most common professions. We will also find 
chiropractor, physiotherapist, veterinary, dentist a.o. in national legal documents, but 
differently regulated either as health personnel or CAM practitioners. We have found 
classifications as CAM practitioner, medical trained personnel, health professional, 
health practitioner, and others. 
In our report we will divide into Practitioner or CAM practitioner. The latest has 
additional CAM training. Medical doctors will be included in this category if 
regulation includes both A and B. 
C. Non-conventional practitioners 
This will include practitioners with short or no medical training and CAM 
practitioners without conventional health education. Classifications could be: Medical 
trained personnel (level under 3 years), non-medical personnel, paramedics, non-
professional health worker, acupuncturist, herbalist, homeopath, osteopath, naprapath, 
physiotherapist, etc. 
 
Summarized we will divide CAM practices into: 
 Medical doctors (MDs): Medical doctors may practice. 
 Medical doctors with CAM:  Medical doctors with CAM training may practice. 
 Conventional practitioner: Conventional practitioners (CPs) (PS3 post-secondary level 
3-4 years may practice (included MD’s). 
 Health professional with CAM: Conventional health personnel with CAM training 
may practice (included MD’s). 
 CAM practitioner: CAM trained personnel, medical trained, DSE diploma post- 
secondary education level) may practice. 
 Others: Others may practise. 
 
1Questionnaire about the status of CAM therapies 
(“CAMbrella” Project, EU FP 7)  
 
NAME OF YOUR COUNTRY: ROMANIA 
 
NAME OF THE CAM THERAPiES: /more could be listed/ 
 
XMedical Acupuncture/ TCM/X  
Anthroposophic Medicine/X  
Homeopathy/ Naturopathy/X  
Ear AcupunctureX/ 
Manual Medicine (Osteopathy,Chiropraxy)/X  
Phytotherapy /X  
Bioresonance therapy/X 
Reflexotherapy, Antroposophic Medicine, X 
Ayurveda Medicine, Mind and Body techniques/ Neuraltherapy, Healing Touch/X 
Alternative massage-moving techniques/XTuina/ ......../............/........ 
 
Please circle the correct answers and feel free to add any information for further clarification. 
More answers are possible. 
 
1. RECOGNITION 
1.1. Is your CAM therapy recognized in your country? 
 xa. Yes, recognized by law 
 xb. Yes, recognized by national medical association/chamber/council 
 c. Yes, recognized by national institute of medico-legal affairs 
 d. No 
 
1.2. Is the profession of this CAM therapy recognized in your country? 
 a. Yes, as a medical specialty 
Xb. Yes, as an additional qualification for medical doctors  
 c. Yes, as an additional qualification for veterinary surgeons 
d. Yes, for other professionals without a full medical or veterinary education (non-medical 
 therapists/practitioners)  
 e. Yes, otherwise, as follows:………………………………. 
 f. No 
 
Questionnaire about the status of CAM therapies 
2 
Reference of official document: there are specialized courses,in 
acupuncture,phytotherapy,homeopathy which are held at the Centre of postuniversitary 
specialization in Bucarest ,Romania………………………………………………… 
 
 
 
 
2. QUALIFICATIONS 
2.1. Are there any official qualifications for doctors in this CAM therapy? 
 a. Yes, as a medical specialty 
b. Yes, diplomas are issued by the national medical association/chamber/council 
Xc. Yes, diplomas are issued by a national doctors association of this CAM therapy and 
recognized by the government 
d. Yes, diplomas are issued by a national doctors association of this CAM therapy and 
recognized by the national medical association/chamber/council 
Xe. Yes, otherwise, namely recognized direct by Ministry of Health  
f. Diplomas are issued by a national doctors association of this CAM therapy, but not 
recognized by the government or the national medical association/chamber/council. 
g. No qualifications at all. 
 
2.2. Are there any official qualifications for non-medical therapists of this CAM therapy? 
a. Yes, diplomas are issued by a national association of ………. therapists and recognized 
by the government 
b. Yes, otherwise, namely ………………………………. 
c. Diplomas are issued by a national association of ……….therapists, but not recognized by 
the government. 
d. No qualifications at all. 
Xe. only medical doctors are authorized for  acupuncture,homeopathy and phytotherapy. 
 
3. TRAINING AT UNIVERSITIES 
3.1. Is CAM therapy part of the undergraduate medical curriculum in your country? 
 a. Yes, as a separate subject  
Questionnaire about the status of CAM therapies 
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 b. Yes, as a part of a course on Complementary and Alternative Medicine. 
 c. Yes, as a part of Traditional Chinese Medicine (in case of acupuncture) 
 d. Yes, it is obligatory for medical students 
 Xe. Yes, it is optional for medical students 
 f. No 
 
 
3.2. How are postgraduate training courses in this CAM therapy for doctors provided in your 
country? 
a. At universities and hospitals of education and research 
b. At private teaching centers 
 c. At both 
 d. At none 
 Xe. As a part of the official Continuous Education Program for Doctors 
 
3.3. Is there a professorial chair for this CAM therapy in your country? 
 a. Yes, at the university/ies of ……………………………. 
b. Yes, a chair shared with other CAM therapies at the university/yes of……. 
  …………………………………………………………. 
 d. If shared with other CAM therapies, please mention them here:  
  ……………………………………………………………….. 
Xe. No. But, there are clinics of acupuncture in some faculties of medicine and hospitals of 
education and research 
 
4. CME (CONTINUING MEDICAL EDUCATION) 
4.1. Is CME in general (conventional) medicine obligatory for all medical doctors in your 
country? 
 Xa. Yes, is controlled by the government 
b. Yes, is controlled by the national medical association/chamber/council 
c. Yes, is controlled by the national doctors association of this CAM therapy 
d. Required number of hours per annum: …………………………………….. 
e. No 
Questionnaire about the status of CAM therapies 
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4.2. Is CME in your CAM therapy obligatory for doctors in your country? 
 a. Yes, is controlled by the government 
b. Yes, is controlled by the national medical association/chamber/council 
c. Yes, is controlled by the national doctors association of this CAM therapy 
d. Required number of hours per annum: ………………………………… 
Xe. No 
 
5. INSURANCE COVERAGE 
5.1. Are the fees for this CAM therapy treatment covered by any insurance? 
 a. Yes, by the national health insurance system 
 b. Yes, by additional private insurance companies 
 c. Yes, complete coverage 
Xd. Yes, partial coverage, namely the acupuncture,phytotherapy,homeopathy,(House of 
National insurance of Health)…………… 
e. No 
 
5. 2. Are the costs for medicines used in this CAM therapy covered by any insurance? 
 a. Yes, by the national health insurance system 
 b. Yes, by additional private insurance companies 
 c. Yes, complete coverage 
d. Yes, partial coverage, namely acupuncture,phytotherapy,homeopathyX…………… 
e. No 
 
 
6.  COLLABORATION 
6.1. Is there any kind of collaboration between different CAM therapies? 
a. Yes, regular meetings 
b. Yes, exchange of newsletters 
c. Yes, conferences 
d. Yes, other, namely………………………… 
Xe. No 
Questionnaire about the status of CAM therapies 
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6.2. Is there any kind of collaboration between your CAM therapy and conventional medicine? 
a. Yes, regular meetings 
b. Yes, report in the national medical journals 
c. Yes, conferences 
d. Yes, other, namely………………….. 
Xe. No 
 
 
7. SOME NATIONAL FIGURES 
7.1. What is the number of medical doctors in your country who practice this CAM therapy? 
 .... (a rough estimation is preferred to no answer at all)  
 
7.2. What is the number of medical doctors in your country who have taken a full training 
curriculum in this CAM therapy, i.e. at the level recommended/required by your association? 
 ...... (a rough estimation is preferred to no answer at all) 
 
7.3. What is the number of doctors of this CAM therapy united in the national professional 
association(s)? ...... 
 
7.4. What is the number of veterinary surgeons in your country who practice this CAM therapy? 
 ....... (a rough estimation is preferred to no answer at all) 
 
7.5. What is the number of therapists in this CAM therapy in your country? 
 ...... (a rough estimation is preferred to no answer at all) 
 
7.6. What is the number of well-trained therapists of this CAM therapy in your country? 
 ...... (a rough estimation is preferred to no answer at all) 
 
7.7. Are there any official documents or scientific papers that describe the use of this CAM 
therapy or CAM in general in your country (number of patients, doctors and/or other 
practitioners)? If so, would you please mention some references? 
Questionnaire about the status of CAM therapies 
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 As far I know there are  official documents which describe the use of the CAM 
therapies.,but I can not mentioned in what 
way………………………………………………………………………………. 
 …………………………………………………………………………………. 
 …………………………………………………………………………………. 
 …………………………………………………………………………………. 
 …………………………………………………………………………………. 
 …………………………………………………………………………………. 
 
Thank you very much for having taken the time to complete the questionnaire! 
For your further information I will let you know about summary if any request! 
 
 
 
contracted by  
Dr. Hegyi Gabriella MD.PhD. 
CAM Departm. of Med. Univ.PECS 
Hungary 
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A Preamble 
This protocol describes the planning details of a systematic review of studies in the 
prevalence of CAM in the 27 EU member states (Austria, Belgium, Bulgaria, Cyprus, Czech 
Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, 
Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Slovakia, Slovenia, 
Rumania, Spain, Sweden and the United Kingdom) and 12 associated countries in FP7 
(Albania, Bosnia & Herzegovina, Croatia, the Former Yugoslav Republic of Macedonia and 
Serbia, Iceland, Israel, Liechtenstein, Montenegro, Norway, Switzerland and Turkey). It is a 
work-in-progress document which will be amended during the course of the review when 
single steps can be planned in more detail or when modifications become necessary. 
Updated versions will receive a new version number and document the changes made. The 
purpose of this protocol is to provide consistency and standardisation in the review process. 
Critical issues will be resolved in discussion, with outcomes documented in this protocol. 
 
B Background 
The use of CAM has increased considerably in Western Countries over the last 20 years, 
evolving towards epidemiological, economical and politically importance for public health.[1-4]  
There is an urgent need to address this area so that we can develop an understanding of the 
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issues surrounding CAM, its availability and its safe and legitimate provision to EU citizens. 
One of the many major drawbacks of existing nationwide surveys on CAM use is the lack of 
standardised terminology that limits reliable comparisons within and between EU member 
states. As a consequence an agreement in this field is essential across the EU so we can 
develop an understanding of what EU citizens utilise which CAM methods and how we 
should develop health policies in this area.  
 
The patients’ needs (WP4) 
The use of specific CAM interventions such as acupuncture (Traditional Chinese Medicine), 
homeopathy, herbal medicine, massage, reflexology and Reiki healing has increased 
exponentially in Western industrialised nations countries over the last 20-25 years.[1-3]  CAM 
is mainly used in addition to conventional care for many chronic and some acute health 
conditions as well as for maintaining health.[5,6]  In comparison to conventional care, CAM 
treatment goals are often more focused on a detailed interest in patients’ wellbeing in 
conjunction with recommendations concerning lifestyle and their quality of life. The WHO 
Centre for Health Development published a global atlas of traditional, complementary and 
alternative medicine by a text and map volume.[4] The authors conclude that for the European 
region CAM is highly prevalent, but were unable to draw a clear picture of CAM use across 
the whole EU as the evidence available has been drawn from just a few EU member states. 
 
The citizens’ needs (WP3) 
While WP4 further examines the perspectives of CAM users across the EU, WP3 begins to 
map the needs and attitudes of EU citizens regarding CAM more broadly. It explores 
questions such as: what are people’s legal rights and/or consumer rights with respect to 
CAM? What are the general information needs about CAM, or the need for safety and quality 
control? What attitudes might people have towards CAM in general, the integration of CAM 
therapies into national healthcare systems or towards individual CAM therapies? 
 
The providers’ needs (WP5) 
The provision and even the definition of various different types of CAM alter from country to 
country. For instance the provision of chiropractic therapies in Scandinavia is very much a 
part of routine medical care, whereas in some countries it has historically been practiced by 
healers in a regulated or unregulated manner. The use of acupuncture and Traditional 
Chinese herbal medicines have become increasingly popular throughout Europe with a 
variety of different and ill- coordinated national legislative frameworks governing use, 
provision, qualifications and registration of providers (practitioners or physicians) and the 
importation of medicinal products. This heterogeneity results in uncertainty for clinicians to 
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understand to whom they might legitimately refer and who might be considered an 
appropriate provider of CAM.  
 
The researchers’ needs (WP7) 
Despite 10 -50% of the population using CAM, the only major EU initiative to develop a 
cogent national research policy for CAM has been as a consequence of the House of Lords 
report [7] which promoted the development of the research capacity. This was a very 
successful but short-lived initiative. Extremely low funding levels of CAM research clearly 
fails to respond to the perceived patient need and the often ill informed debate that surrounds 
CAM provision.[8]  In addition, high quality scientific research demands a clear strategy based 
on consensus-based standardised terminology and understanding of prevalence in the 
population. This information is sorely lacking in the current literature and for the most part 
lacks adequate scientific quality.  
Because of the integrative and often holistic nature of CAM therapies in comparison to 
conventional medicine, the framework of research and assessment strategies should also be 
consistent in evaluating this complex intervention.[9-11] 
 
The stakeholders’ needs 
As Europe becomes increasingly federalised and the healthcare provision of its citizens 
becomes a matter of both national and regional importance, providing safe cost-effective and 
clinically therapeutic CAM treatments becomes increasingly important. It is essential for all 
stakeholders, including consumers and providers, law and policy makers, as well as the CAM 
pharmaceutical industry, that we create an understanding of what is legitimate and safe 
practice, who should be providing it and whether it should be funded as a medical 
intervention. 
 
C Objectives: 
The initial phase of CAMbrella is a comprehensive evaluation of the of types of CAM and 
their respective terminology (WP1), what are the needs and attitudes of the citizens 
regarding CAM (WP3), who uses CAM (WP4), who provides CAM (WP5) and what research 
methods are used to identify population-based CAM prevalence and use (WP7) in EU39 
(Figure 1).  
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Figure 1: Aspects of CAM prevalence included in literature review 
 
This review will collect (normally cross-sectional) population-based studies in 39 European 
countries which evaluate the prevalence of CAM in the above components. 
Subsequent literature reviews in WP 7 will evaluate (a) research results (effectiveness, 
efficacy, cost-effectiveness, safety) in the main CAM therapies elucidated through this review 
and (b) concepts of CAM research methodology world-wide. Separate protocols for these 
literature reviews will be created. Together with input from expert opinion makers, these 
reviews will form a consensus-based road map for future CAM research. 
 
D Literature search 
We will concentrate our searches in the following databases: 
1. Ovid MEDLINE 
2. Cochrane Library 
3. CINAHL 
4. EMBASE 
5. PsychINFO including PsychARTICLES 
6. Web of Science 
7. AMED 
8. CISCOM Database 
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In addition, we will hand-search reference lists of included studies and request further 
potentially relevant publications from the personal files of CAMbrellians and other CAM 
experts. We will also conduct citation searches for all included studies, and search the 
reference lists of previously published reviews.  A specific search protocol for grey literature 
will be developed by the University of Southampton and integrated into this search strategy. 
 
a. Literature search terms 
Limits 1. 01 January 1989 through 31 December 2009 
2. Human studies 
Terms  (MeSH or free text keywords when MeSH not accepted)  
 AND AND OR 
Complementary therapies 
[MeSH exploded]$ 
Data collection [MeSH 
exploded]$ 
Europe [MeSH 
exploded]$ 
 
 
Complementary medicine Survey Turkey 
complementary therap* questionnaire Israel 
alternative medicine* Epidemiology  
alternative therap* Prevalence  
integrative medicine* Needs assessment  
integrative therap* 
Health services research 
[MeSH exploded]$ 
 
unconventional medicine* Demand  
unconventional therap* Reason*  
Supplement* Expectation*  
herbal Motivation*  
homeopathy Belief*  
osteopathy Acceptance  
acupuncture Value*  
traditional Chinese medicine Philosophy  
mind-body therap* World view  
Naturopathy Public  
Meditation Lay public  
Massage Population  
Ayurveda Consumer  
Chiropractic medicine Access barriers  
Manipulation Access trends  
Biofield therap* Patterns of use  
Reiki Barriers  
Therapeutic touch Registration  
Yoga Necessity  
aromatherapy Requirement*  
prayer Consumer choice  
XXX Knowledge inclination  
 Approach  
 Outlook  
 Position  
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Limits 1. 01 January 1989 through 31 December 2009 
2. Human studies 
Terms  (MeSH or free text keywords when MeSH not accepted)  
 AND AND OR 
 Opinion   
 Point of view  
 Inhabitant*  
 Resident*  
 Frequency  
 Popularity   
 Predominance  
 Occurance  
 Incidence   
 Pervasiveness  
   
$see Appendix II 
 
E Literature inclusion criteria 
To be included in the review the studies must meet the following criteria: 
1. Design: 
a. Population-based study AND 
b. Cohort study OR 
c. Cross-sectional study  
2. Participants: 
a. Those receiving CAM therapies that are broadly consistent with 
NCCAM definition 
b. in any EU39 country 
c. all ages 
d. assessment of at least one socio-demographic variable 
3. Languages: 
a. any EU39 language (may need to be modified, depending on 
availability of qualified translators) 
4. Outcome: 
a. Reports the prevalence of use in the general population of 
either: 
i. CAM in general, or  
ii. one or more specific CAM modalities 
 
In addition, for specific literature reviews conducted by the relevant WP, the following 
inclusion criteria can apply 
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1. Health care needs assessment, safety and information needs, and 
attitudes towards CAM (for WP3) 
2. Description of provider of CAM therapy (for WP5) 
3. Statistical assessment of at least one health-related characteristic (for 
WP7) 
 
F Literature exclusion criteria 
1. non-peer-reviewed journal 
2. non-cross-sectional or non-cohort studies 
3. qualitative studies  
4. editorial, letter, theses, dissertations, case study, congress abstracts 
(1) accepted theses and dissertations may be included if they 
meet the inclusion criteria in E. above  
5. unpublished and ongoing trials 
6. presentation as abstract only 
7. no abstract 
8. double publication found in different databases 
9. focus exclusively on CAM use in disease-specific populations (e.g. 
cancer) 
 
G Selection of studies 
An electronic database (Reference Manager or EndNote) will be used to maintain the search 
results. One reviewer will check all hits of the literature search and exclude clearly irrelevant 
articles based on titles and abstracts. Articles excluded at this stage are those not at all 
related to the prevalence of CAM use.  The number of articles excluded at this stage will be 
recorded, but specific reasons for exclusion will not be recorded (beyond ‘clearly irrelevant’).  
As some articles excluded for the prevalence review may in fact be appropriate for inclusion 
by the other WPs, the saved searches will be available to members of other WPs by 
requesting Sue Earley’s (S.Eardley@southampton.ac.uk) log-in and password details. 
Titles, abstracts, and (if necessary) full text copies of all remaining articles will then be 
assessed by at least two reviewers independently for eligibility. Publications will be excluded 
only on agreement between the two reviewers. At this stage, reasons for excluding each 
article will be documented in the database, according to the exclusion criteria listed above.  
Disagreements will be documented and resolved by discussion (if necessary by a third 
reviewer). Inter-rater agreement will be calculated by Cohen's kappa. If several reports for a 
single study are published, all publications will be reviewed if they meet eligibility criteria.  
Full text copies of all eligible papers will be obtained and translated into English if necessary. 
This database and electronic copies of articles will also be made available to the other WPs. 
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H Assessment of study quality and risk of bias 
To evaluate quality, a catalogue of 18 questions organised in 4 domains will be answered 
plus a section for overall comments raising important concerns (Appendix 1). The questions 
are weighted for importance for overall study quality by assignment of points. This quality 
assessment tool is based on the STROBE Statement checklist for observational studies [12] 
plus one item addressing conflict of interest and has been used in previous evaluations of 
CAM prevalence. [13] 
Aspects of methodological and reporting quality will be assessed by at least two reviewers 
independently for a subsample of approximately 20% of the studies. Inter-rater agreement 
will be calculated by Cohen's kappa. Disagreements will be documented and resolved by 
discussion (if necessary by a third reviewer). If agreement on this subsample is low (<.9), the 
remaining 80% of studies will also be assessed by the second reviewer.  The results will be 
presented in a table with each item listed with its points received plus a summary score.  
 
I Data extraction 
Each work package will be responsible for extraction of data pertinent to their topic. WP4 will 
extract common variables for all WP in addition to those for WP4 (i.e. variable 1-74). Two 
reviewers will extract information independently using a pre-tested standardised form specific 
for the respective review and work package. The second reviewer will extract information for 
a subsample of approximately 20% of the studies only. Inter-rater agreement will be 
calculated by Cohen's kappa. Disagreements will be documented and resolved by discussion 
(if necessary by a third reviewer). If agreement on this subsample is low (<.9), the remaining 
80% of studies will also be assessed by the second reviewer.  The following is an initial table 
of possible extraction variables and will be developed further by the WP teams. 
 
Extraction variables 
 Definition/Explanation Values 
Common variables for all WPs 
1. Study ID-Number generated by reviewer  
2. Reviewer initials Corresponding to list of names  
3. Title of publication Full title of article  
4. Year of publication Year article was published Year  
5. First author First author’s surname and first 
initial 
 
6. Journal title Full title of journal  
7. Publication details of 
article 
Journal issue 
Journal volume 
Article page numbers 
 
8. Place of research Country where research conducted  
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 Definition/Explanation Values 
9. Language of publication Language that article was written in. 
Abstract must be in English 
 
10. Definition of CAM in 
paper 
Type of CAM definition on which the 
research was based, as indicated in 
paper 
(1) NCCAM  
(2) Cochrane collaboration 
(3) BMA  
(4) WHO 
(5) House of Lords 
(6) Eisenberg (1993) 
(7) Ernst & Cassileth 
(1998) 
(8) Zollman & Vickers 
(1999) 
(9) Other (describe) 
11. CAM Definition  Direct quote of definition used in 
article 
 
12. Year of data collection Year that data was collected (not 
year published nor year of 
diagnosis) 
Year  
13. Study objective Direct quote from article of what the 
authors wanted to study 
 
14. Length of recruitment 
period 
How long from initial questionnaire 
to establishment of sample 
population 
 
15. Ethical approval Statement of whether the study had 
been approved by IRB or similar 
ethics committee 
(0) not described 
(1) approved by ethical 
committee 
16. Sampling method Direct quote from article describing 
the sampling method 
 
17. Study design Stated type(s) of study design in 
article 
(1) cross-sectional 
(2) cohort study 
(3) multi-centre 
(4) single centre 
(5) other 
18. Type of questionnaire 
used 
State whether questionnaire was 
piloted (used in a small group, 
evaluated and changed if necessary 
before general use), validated 
(validity statistically analysed 
against other markers to 
corroborate results) etc. 
(0) not stated 
(1) piloted 
(2) validated 
(3) based on previous 
questionnaire 
(4) non-validated 
questionnaire 
19. Sample size Number of participants: i.e. 100 
questionnaires sent out and 80 
returned, sample size is 80 
 
20. Participation rate Response rate is the proportion (%) 
of people participating in study out 
of the selected study population. 
(e.g. if 100 questionnaires were 
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 Definition/Explanation Values 
sent out and 80 returned, the 
participation rate is 80%) 
21. Number of patients 
receiving CAM therapy 
Number of patients receiving CAM 
therapy as proportion (% to 1 
decimal) of total sample size. i.e if 
sample size was 80 and 45 people 
received CAM: 45/80, 56.3% 
x/N (number of CAM 
patients/sample size), % 
22. Age of whole sample* The age range and/or mean 
age±standard deviation (SD) of all 
participants in the sample 
(=sample size) inclusive of 1 
decimal point  
Age range and/or mean 
age±SD 
(0) = not described 
23. Age of CAM users* The age range and/or mean 
age±standard deviation (SD) of 
CAM users inclusive of 1 decimal 
point   
Age range and/or mean 
age±SD 
(0) = not described 
24. Age of non-CAM users* The age range and/or mean 
age±standard deviation (SD) of 
non-CAM users inclusive of 1 
decimal point   
Age range and/or mean 
age±SD 
(0) = not described 
25. Gender of whole 
sample* 
The fractions and % of male and 
female patients of all participants 
in the sample (N=sample size) 
M: x/N, % 
F: x/N, % 
(0) = not described 
26. Gender of CAM users* The fractions and % of male and 
female patients of CAM users 
(n=CAM users) 
M: x/n, % 
F: x/n, % 
(0) = not described 
27. Gender of non-CAM 
users* 
The fractions and % of male and 
female patients of non-CAM users 
(n=non-CAM users) 
M: x/n, % 
F: x/n, % 
(0) = not described 
28. Ethnicity of whole 
sample* 
The different ethnicities of all 
participants in the sample listed 
with fraction and % of whole sample 
(N=sample size) 
Ethnicity, x/N, % 
(0) = not described 
29. Ethnicity of CAM users* The different ethnicities of CAM-
users listed with fraction and % of 
CAM users (n=CAM users) 
Ethnicity, x/n, % 
(0) = not described 
30. Ethnicity of non-CAM 
users* 
The different ethnicities of non-
CAM-users listed with fraction and 
% of non-CAM users (n=non-CAM 
users) 
Ethnicity, x/n, % 
(0) = not described 
31. Marital status of whole 
sample* 
The different marital status of all 
participants in the sample listed 
with fraction and % of whole sample 
(N=sample size) 
Marital status, x/N, % 
(0) = not described 
32. Marital status of CAM 
users* 
The different marital status of CAM-
users listed with fraction and % of 
CAM users (n=CAM users) 
Marital status, x/n, % 
(0) = not described 
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 Definition/Explanation Values 
33. Marital status of non-
CAM users* 
The different marital status of non-
CAM-users listed with fraction and 
% of non-CAM users (n=non-CAM 
users) 
Marital status, x/n, % 
(0) = not described 
34. Education levels of 
whole sample* 
The different education levels of all 
participants in the sample listed 
with fraction and % of whole sample 
(N=sample size) 
Education level, x/N, % 
(0) = not described 
35. Education levels of CAM 
users* 
The different education levels of 
CAM-users listed with fraction and 
% of CAM users (n=CAM users) 
Education level, x/n, % 
(0) = not described 
36. Education levels of non-
CAM users* 
The different education levels of 
non-CAM-users listed with fraction 
and % of non-CAM users (n=non-
CAM users) 
Education level, x/n, % 
(0) = not described 
37. Income levels of whole 
sample* 
The different income levels of all 
participants in the sample listed 
with fraction and % of whole sample 
(N=sample size) 
Income level, x/N, % 
(0) = not described 
38. Income levels of CAM 
users* 
The different income levels of CAM-
users listed with fraction and % of 
CAM users (n=CAM users) 
Income level, x/n, % 
(0) = not described 
39. Income levels of non-
CAM users* 
The different income levels of non-
CAM-users listed with fraction and 
% of non-CAM users (n=non-CAM 
users) 
Income level, x/n, % 
(0) = not described 
40. Employment status of 
whole sample* 
The different employment statuses 
of all participants in the sample 
listed with fraction and % of whole 
sample (N=sample size) 
Employment status, x/N, % 
(0) = not described 
41. Employment status of 
CAM users* 
The different employment statuses 
of CAM-users listed with fraction 
and % of CAM users (n=CAM 
users) 
Employment status, x/n, % 
(0) = not described 
42. Employment status of 
non-CAM users* 
The different income levels of non-
CAM-users listed with fraction and 
% of non-CAM-users (n=non-CAM 
users) 
Employment status, x/n, % 
(0) = not described 
43. Condition(s) treated with 
CAM 
The different conditions and number 
of patients with this condition 
treated with CAM listed with fraction 
and % of whole sample (n=CAM 
users) 
Condition treated with 
CAM, x/n, %  
44. Length of condition 
treated with CAM 
For each condition listed above, list 
number of years patients have had 
illness or condition 
mean years±SD and/or 
range  
45. Reasons for using CAM   The reasons mentioned in paper will Reason for using CAM, x/n  
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 Definition/Explanation Values 
be listed with the number of CAM 
users who stated this reason. 
(n=CAM users). They will later be 
grouped into categories. 
Possible categories  
- Cure illness 
- Complementary’ 
- To avoid side-effects of 
conventional medicine  
- Treatment of side-effects of 
conventional medicine 
- For enhanced physician-patient 
interaction 
- Prevent recurrence of disease 
- Maintain good health/overall well-
being 
- Boost immune system 
- Explore every treatment option 
- biomedical treatment ineffective or 
unsuccessful  
- Other (does not fit into any other 
category  
(1) Reason not given: Some papers 
may have participants who did not 
give any reason. The percentage 
and fraction of participants who did 
not give a reason will be under this 
category. 
(2) N/A: If the paper did not 
investigate the reasons for using 
CAM, the entire column is denoted 
with N/A  
 
The percentage is calculated from 
the number of CAM users who 
selected a reason divided by the 
overall number of CAM users. As 
one person could list more than one 
reason of CAM use, the total % 
could be >100%. (n=CAM users). 
(0) not evaluated 
(1) Reason not given, x/n, 
%, N/A 
(2) N/A 
 
 
46. Reasons for not using 
CAM 
The reasons mentioned in paper will 
be listed with the number of non-
CAM users who stated this reason. 
(n=non-CAM users). They will later 
be grouped into categories. 
(1) Reason not given: Some papers 
may have participants who did not 
Reason for not using CAM, 
x/n  
(0) not evaluated 
(1) Reason not given, x/n, 
%, N/A 
(2) N/A 
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 Definition/Explanation Values 
give any reason. The percentage 
and fraction of participants who did 
not give a reason will be under this 
category. 
(2) N/A: If the paper did not 
investigate the reasons for not using 
CAM, the entire column is denoted 
with N/A  
47. Type of specific 
practitioner- or 
physician-prescribed 
CAM modalities used 
List each modality that was 
prescribed or delivered by a 
practitioner or physician. A 
modality is defined as a technique 
of applying a therapeutic regimen or 
agent.[14] 
 
48. Setting where specific 
practitioner- or 
physician-prescribed 
CAM modality was 
delivered 
For each practitioner- or physician-
prescribed CAM modality listed 
above, list where the service was 
delivered, e.g. GP’s office, hospital, 
integrated clinic, private clinic etc. 
 
49. Number (% of whole) of 
patients using specific 
practitioner- or 
physician-prescribed 
CAM modalities  
For each practitioner- or physician-
prescribed CAM modality listed 
above, list number of patients and 
% of whole sample of each 
practitioner- or physician-prescribed 
CAM modality (N=sample size). As 
one person could list more than one 
type of CAM modality, the total % 
could be >100% 
x/N , % 
50. Number (% of CAM-
users) of patients using 
specific practitioner- or 
physician-prescribed 
CAM modalities 
For each practitioner- or physician-
prescribed CAM modality listed 
above, list number of patients and 
% of CAM users (n=number of 
CAM users). As one person could 
list more than one type of CAM 
modality, the total % could be 
>100% 
x/n, % 
51. Time period of specific 
practitioner-prescribed 
CAM modalities 
For each practitioner- or physician-
prescribed CAM modality listed 
above, list when the modality was 
used 
(0) not stated 
(1) ever 
(2) in the past 12 months 
52. Duration of CAM use of 
specific practitioner- or 
physician-prescribed 
CAM modalities 
For each practitioner- or physician-
prescribed CAM modality listed 
above, list for how long the modality 
was used 
Number of months 
53. Level of CAM use 
(Kristoffersen criteria[15]) 
Classification of patient’s exposure 
to CAM 
(CAM1):Seen a CAM 
practitioner at least 4 times 
(CAM2): Seen a CAM 
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practitioner at least once 
(CAM3): Use of CAM 
provider, OTC-products or 
CAM techniques 
(CAM4): Use of a CAM 
provider, OTC-products, 
CAM techniques or special 
diets 
(CAM5): Use of a CAM 
provider, OTC-products, 
CAM techniques, special 
diets or exercise 
(CAM6): All CAM use 
including prayer 
 
54. Outcomes of specific 
practitioner-prescribed 
CAM modalities 
For each practitioner- or physician-
prescribed CAM modality listed 
above, list any evaluated outcome 
results  
 
55. Satisfaction of specific 
practitioner- or 
physician-prescribed 
CAM modality 
For each practitioner- or physician-
prescribed CAM modality listed 
above, list number of patients and 
% of CAM-users in each level of 
satisfaction (n=number of CAM 
users) 
x/n in each level of 
satisfaction 
56. Type of specific self-
prescribed or purchased 
CAM modalities used 
List each modality that was self-
prescribed or self-purchased 
 
57. Number (% of whole) of 
patients using specific 
self-prescribed or 
purchased CAM 
modalities  
For each self-prescribed or self-
purchased CAM modality listed 
above, list number of patients and 
% of whole sample of each self-
prescribed or self-purchased 
CAM modality (N=sample size). As 
one person could list more than one 
type of CAM modality, the total % 
could be >100% 
x/N , % 
58. Number (% of CAM-
users) of patients using 
specific self-prescribed 
or purchased CAM 
modalities 
For each self-prescribed or self-
purchased CAM modality listed 
above, list number of patients and 
% of CAM users (n=number of 
CAM users). As one person could 
list more than one type of CAM 
modality, the total % could be 
>100% 
x/n, % 
59. Time period of specific 
self-prescribed or 
For each self-prescribed or self-
purchased CAM modality listed 
(1) ever 
(2) in the past 12 months 
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purchased CAM 
modalities 
above, list when the modality was 
used 
(3) not stated 
60. Duration of CAM use of 
specific self-prescribed 
or purchased CAM 
modalities 
For each self-prescribed or self-
purchased CAM modality listed 
above, list for how long the modality 
was used 
Number of months 
61. Outcomes of specific 
self-prescribed or 
purchased CAM 
modalities 
For each self-prescribed or 
purchased CAM modality listed 
above, list any evaluated outcome 
results  
(0) not described 
62. Satisfaction of specific 
self-prescribed or 
purchased CAM 
modality 
For each self-prescribed or 
purchased CAM modality listed 
above, list number of patients and 
% of CAM-users in each level of 
satisfaction (n=number of CAM 
users) 
x/n in each level of 
satisfaction 
63. Other co-morbidities of 
patients 
List any co-morbidities of patients (0) not described 
64. Use of conventional 
treatments with CAM 
List any conventional medical 
treatments used for illnesses 
treated also with CAM 
(0) not described 
65. Use of conventional 
treatments for illness not 
treated with CAM 
List any conventional medical 
treatments used for illnesses not 
treated with CAM 
(0) not described 
66. Key conclusions from 
authors 
Direct quote of key conclusions  
67. Comments of author Note any significant comments 
regarding limitations, etc. listed by 
author 
(0) no comments 
68. Study funding source List the source of funding for the 
study, as stated by the authors 
(0) not stated 
69. Correspondence 
required 
Note any necessary 
correspondence with author 
 
70. Reference to other 
studies 
  
71. Comments of reviewer Any comments to study from 
reviewer 
 
72. Quality of study 
(based on evaluation 
Appendix 1) 
Final % grade of quality  
73. Eligible for inclusion in 
review 
Judgement of eligibility by reviewer  (0) no 
(1) yes 
74. Reason for exclusion 
from review 
List reason for exclusion from this 
literature review 
(1) not population-based 
Variables specific to WP1 
75. definition of CAM in 
manuscript 
Same as 11  
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76. definitions and 
terminology of CAM 
therapies in manuscript 
Same as 46 and 54  
77. Historical background to 
CAM definition 
Historical connotation of CAM 
modalities as defined in manuscript 
(0) not stated 
Additional variables specific to WP3 
78. What information about 
CAM do citizens want 
and need? 
List given types of information about 
CAM therapies e.g. safety, side 
effects, therapeutic value, 
registration 
(0) not described 
79. From whom do citizens 
access and want to get 
information about CAM? 
List sources of information about 
CAM e. g. physician, nurses, CAM 
practitioner, Internet, national health 
boards, consumer councils, etc. 
(0) not described 
80. What type(s) of CAM 
therapies are desired 
and used? 
List given types of CAM therapies 
described by patients as desirable 
and used 
(0) not described 
81. For what illnesses or 
conditions are CAM 
therapies desired? 
List given illness or conditions for 
which CAM therapies are desirable 
and used 
(0) not described 
82. What attitudes do 
citizens hold about 
CAM?  
List views on: CAM in general, 
individual CAM therapies, the 
integration of CAM into national 
health services, and training of CAM 
practitioners 
 
Additional variables specific to WP4 
83. Out-of-pocket (OOP) 
expenditure on CAM 
therapy 
For each type of CAM modality 
listed above, list what patient paid 
OOP for CAM therapy, with 
currency 
mean±SD and currency 
(0) not described 
84. Health insurance 
expenditure on CAM 
therapy 
For each type of CAM modality 
listed above, list what the health 
insurance paid for CAM therapy, 
with currency 
mean±SD and currency 
(0) not described 
85. Total cost of CAM 
therapy 
For each type of CAM modality 
listed above, list total cost of CAM 
therapy and currency 
mean±SD and currency 
(0) not described 
86. Health insurance 
coverage of CAM 
List whether CAM therapy was 
covered by health insurance 
(0) not described 
(1) complete coverage 
(2) partial coverage 
(3) no coverage 
Additional variables specific to WP5 
87. Type of practitioner or 
physician delivering 
treatment 
For each type of CAM modality 
listed above, list type of practitioner 
or physician delivering treatment 
(0) not described 
88. Training of practitioner or 
physician 
For each type of CAM modality 
listed above, list training of 
(0) not described 
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practitioner or physician delivering 
treatment 
89. Age of practitioner or 
physician 
For each type of CAM modality 
listed above, list age of practitioner 
or physician delivering treatment 
(0) not described 
90. Gender of practitioner or 
physician 
For each type of CAM modality 
listed above, list gender of 
practitioner or physician delivering 
treatment 
(0) not described 
91. Ethnicity of practitioner 
or physician 
For each type of CAM modality 
listed above, list ethnicity of 
practitioner or physician delivering 
treatment 
(0) not described 
92. How CAM is provided  For each type of CAM modality 
listed above, list how and where the 
CAM therapy is delivered 
(0) not described 
Additional variables specific to WP7 
93. statistical methods used 
in analysis 
List stated statistical methods used 
to calculate prevalence 
(0) not described 
94. Missing data Describe whether missing data was 
imputed 
(0) not described 
(1) imputed 
95. Method of missing data 
imputation 
Describe method of missing data 
imputation 
(0) not described 
(1) method 
   
 
*If results are reported separately for different groups (i.e. children/adults, men/women, etc), 
the following variables should be extracted for each individual group. 
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